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ABSTRACT OF THE DISSERTATION
MOLECULAR MECHANISM(S) OF ZIKA VIRUS INFECTION AND ASSOCIATED
NEUROPATHOGENESIS
by
Chet Raj Ojha
Florida International University
Miami, Florida
Professor Nazira El-Hage, Major Professor
Zika virus (ZIKV), a mosquito-borne flavivirus, is known to induce various
neurodevelopmental disorders including microcephaly and growth retardation in newborns
from infected mothers. However, the exact mechanism of ZIKV-associated
neurodevelopmental disorders is still unknown. The study was aimed at identifying the
molecular mechanism(s) of ZIKV infection using in-vitro and in vivo methods. Using three
isolated strains of ZIKV (MR766, R103451, and PRVABC59), we show that the Asian
strains of ZIKV are more infective and toxic to glial cells and neurons compared to the
African strain. Infection by PRVABC59 induces markedly higher release of inflammatory
molecules; IP10, RANTES, IL-6, and IFN-β. ZIKV cellular entry in glial cells is primarily
mediated by Axl receptor irrespective of the viral strains. We show that ZIKV induces
unfolded protein response (UPR), toll-like receptor (TLR) and autophagy pathways in the
glial cells. Exploring the role of these pathways in ZIKV infection, we report that
pharmacological and genetic inhibition of TLR3 causes a marked decrease in ZIKV titers
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and the viral-induced inflammatory response in infected glial cells, while Beclin1, an
autophagy protein having a crucial role in the initiation of autophagosome formation,
controls the ZIKV-induced host inflammatory responses. We further investigated the role
of Beclin1, in the development of neuropathology in-utero using ZIKV-exposed fetus.
ZIKV-infected timed-pregnant wild-type C57BL/6J and Beclin1 deficient (Atg6+/-) mice
showed that the Beclin1 protein plays a protective role in both growth and embryonic brain
development in the fetus. Mechanistically, deficiency of Beclin1 causes the reduction in
microcephaly related genes (MCPH1, ASPM, CASC5, and WDR62) in the fetal brain,
which correlate with the overt congenital malformations and growth impairment in fetus
and pups born from Atg6+/- mice. Since viral protein (NS1and Env) were detected in pup’s
brain in the absence of ZIKV genome, we reason that viral proteins transmigrated from the
placenta to the fetus by a yet unknown mechanism, probably the secretory autophagy,
might be the causal factors for the neurodevelopmental disorder detected in pups born from
infected mice.
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CHAPTER 1: INTRODUCTION
1.1.

Introduction of Zika Virus
Zika virus (ZIKV) is a member of Flavivirus genus and closely related to other

clinically important flaviviruses including Dengue virus (DENV), West Nile virus (WNV),
Chikungunya virus (CKV) and Japanese encephalitis virus (JEV) [1]. In terms of historical
timeline, ZIKV was first isolated in 1947 from monkey host in the Zika forest of Uganda
during a yellow fever surveillance program. A few years later in 1952, a neutralizing
antibody against ZIKV was isolated from human sera [2, 3]. The first major human
outbreak of ZIKV infection was reported in Yap Island of Micronesia in 2007 followed by
a major public health concern from outbreaks in French Polynesia in 2013 and most
recently in Brazil, where the infection was linked to increased prevalence of Guillain-Barre
syndrome (GBS) and microcephaly, respectively [4, 5]. In a case study of French
Polynesians diagnosed with GBS, infection by ZIKV was reported in ninety-eight percent
(41 out of 42) of patients by the detection of anti-ZIKV-IgM or anti-ZIKV-IgG antibodies.
In the study, every individual cases with GBS had neutralizing antibodies against ZIKV,
as compared to 56% detected in the control population [6]. In Colombia, 42% of people
who tested positive for ZIKV were diagnosed with GBS; reflecting the increase in cases of
this disease with the ZIKV outbreak in 2015-2017 [7]. In July 2015, the Brazilian
department of health announced a direct association between ZIKV and GBS and three
months later, ZIKV was reported to be the main cause related to the congenital abnormality
detected in microcephalic newborns. A retrospective analysis of ZIKV outbreak in French
Polynesia further provided an evidence for maternal ZIKV infection in the first trimester
of pregnancy as the risk factor for microcephaly in fetuses [8].
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A great deal of attention was placed on the spread of and protection against the Aedes
mosquitos, as they are the predominant species of mosquitos transmitting the virus. ZIKV
primarily is a sylvatic virus transmitted between mosquitos and non-human primates.
Aedes albopictus and Aedes aegypti are the most commonly responsible vectors for ZIKV
transmission with A. aegypti being associated with the latest outbreak in South America.
After the recent outbreaks, it became clear that ZIKV transmission was not limited to the
mosquito-borne route. Several cases of human to human ZIKV transmission possibly via
sexual contact have already been reported [9, 10]. Detection of viral particles in breast milk
and evidence of viral damage in the placenta of ZIKV infected mother further indicates the
possibility of vertical transmission [11, 12]. Human to human transmission via sexual
contact, body fluids, and blood transfusion is the unique feature of ZIKV compared to other
flaviviruses and might be the factor enhancing the stability of ZIKV in different body fluids
and the broad viral tropism [13].
Similar to other flaviviruses, ZIKV is an enveloped and icosahedral virus having
single-stranded positive-sense RNA as a genome. The RNA is about 11 kb long and
contains a single open reading frame (ORF) flanked by noncoding regions on both 5’ and
3’ sides [14, 15]. The ORF encodes a polyprotein of 3419 amino acids that is cleaved by
both host and viral proteases post-translationally into the capsid (C), precursor of the
membrane (prM), envelope (E) and 7 nonstructural proteins (NS1, NS2A, NS2B, NS3,
NS4A NS4B, and NS5) (Figure 1) [16]. In addition to controlling viral transcription and
replication, the NS proteins are involved in attenuating host antiviral responses [17-19],
while the envelope (E) protein mediates cellular attachment, entry, and fusion and is the
primary target for neutralizing antibodies [20, 21].
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Figure 1. Structure and genome of ZIKV.
1.2.

Spatiotemporal variants of ZIKV and how they translate to the pathogenesis
Genetic and phylogenetic studies have revealed that ZIKV has evolved from 3

distinct lineages including the West African (Nigerian cluster), the East African (MR766
prototype cluster), and the Asian lineage (Figure 2). Genetic studies on the NS5 gene
indicate that ZIKV was most likely originated from East Africa and spread towards West
Africa and Asia approximately 50–100 years ago [22, 23]. The African lineage viruses
were sporadically associated with human infections over the past century whereas the
Asian lineages have emerged as a new public health burden because of their capacity of
transmitting from human to human and causing neurological abnormalities [24]. Genetic
changes among the ZIKV lineages are attributed to the global spread of new phenotypes
and emergence of increased neuropathogenicity. Phylogenetic and amino acid variant
analysis of the spatiotemporally different strains of ZIKV; MR766 (Uganda 1947),
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FSS13025 (Cambodia 2010), P6-740 (Malaysia 1966), PRVABC59 (Puerto Rico 2015),
and DAKAR 41519 (Senegal 1984); revealed their distinct lineages and significant amino
acid differences in the viral polyprotein. Higher levels of accumulated changes were
reported in the envelope protein, the terminal region of the prM, the NS2A and the NS5
protein regions of ZIKV genomes [24].

Figure 2. Phylogenetic classification showing the potential origin and spread of ZIKV.
Lineage-specific differences in ZIKV infectivity, virulence and pathologies have
been reported using in vivo mouse and in vitro cell culture model system. Studies in which
either the signal transducer and activator of transcription-2 knock out (Stat2-/-) or the
interferon alpha receptor 1 knock out (Ifnar1-/-) mouse model were used, showed that the
Asian strains including the Puerto-Rican, Malaysian and Cambodian strains of ZIKV
caused delayed onset of disease, less severe disease phenotypes and lower lethality rates
when compared to the African strains (MR766) of ZIKV [24]. However, others have
reported that both the Asian strain (H/PF/2013) and the African strain (Dakar 41519) had
similar virulence and caused 100% lethality in the Ifnar-/- mouse model in a different study
[25]. The French Polynesian strain (H/PF/2013) is reported to be more lethal compared to
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the other viral strains within the Asian lineage of ZIKV. The inconsistency between the
studies in regards to the Asian strains might be related to the inherent differences within
the specific lineages, differences in their amino acid sequences and the study design
including the viral inoculation dose. Nonetheless, these studies have revealed the
differences in pathogenesis and lethality associated with spatiotemporally different ZIKV
lineages or strains.
In vitro studies have reported a higher infection rate in neural stem cells (NSCs)
and astrocytes with the African lineage ArB41644 as compared to the Asian lineage
PRVABC59 and H/PF/2013. Also, NSCs infected with ArB41644 showed higher levels of
cell cycle impairment and antiviral response when compared to cells infected with
PRVABC59 and H/PF/2013. The same study also reported a significant up-regulation in
the genes encoding for DExD/H-Box helicase 58 (DDX58), interferon induced with
helicase C domain 1 (IFIH1), toll-like receptor-3 (TLR3), and interferon beta 1 (IFNB1)
and downregulation of C-X-C motif chemokine ligand 8 (CXCL8) in NSCs infected with
African strains, while significant down-regulation in the genes encoding for the C-X-C
Motif chemokine ligand 10 (CXCL10), caspase 1 (CASP1) and cathepsin S (CTSS) was
reported in NSCs infected with Asian strains [26]. These findings further suggest that the
molecular mechanism underlying ZIKV infection and pathogenesis might be lineagespecific and a single therapeutic approach targeting the African lineage may not necessarily
be effective against the Asian lineage of ZIKV.
1.3.

Mechanism of ZIKV entry into the cells: the role of TAM receptors
Similar to other members of the Flavivirus, ZIKV enters the cell presumably by

receptor-mediated endocytosis [27, 28]. However, the molecular mechanisms of viral entry
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into brain cells and the associated pathologies are still poorly understood. Current studies
suggest that Tyro3 Axl MER (TAM) family of receptors are shown to be the primary entry
factors for ZIKV in various cell types [28, 29]. TAM is a subfamily of receptor tyrosine
kinase (RTK) having distinctive domain structure and a unique KW(I/L)A(I/L)ES
sequence in their catalytic domain. They contain two immunoglobulins like ectodomains,
two fibrinolectin type III domains, a hydrophilic transmembrane domain, and the
intracellular tyrosine kinase domain. The receptor has two traditional ligands; the growth
arrest-specific-6 (Gas6) and the protein S [30]. Gas6 can activate all three receptors in the
order of Axl> Tyro3>> MERTK, while protein S can activate tyro3 and MERTK. The
tyrosine kinase activity of the TAM receptors has an important role in controlling excessive
inflammation by dampening the innate immune response in cells, in promoting tissue
repairs and in clearance of apoptotic cells [31].
Out of the three TAM receptors, Axl is the most studied receptor in regards to ZIKV
infection and was originally cloned from cancer cells [32]. Axl is involved in the innate
immune response as well as other cellular mechanisms including proliferation, migration,
and aggregation in different cell types [33, 34]. Exposure to neutralizing antibody against
Axl or by gene silencing using small interfering RNA targeting the Axl gene led to a
decrease in viral replication and infection, suggesting a role of Axl as a putative ZIKV
entry receptor in human fibroblast cells [35]. Human microglia and astrocytes isolated from
developing brain express Axl receptors. Inhibition of Axl by synthetic decoy receptor
(MYD1) and Axl kinase inhibitor (R428) have been shown to inhibit ZIKV infection in the
glial cells [28].
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1.4.

Molecular mechanisms potentially involved in the pathology of ZIKV
Once the virus has made its way inside the host, an integrated defense network

comprising of innate and adaptive immune responses works together to thwart viral
infections [36]. Viruses and their components are sensed by the host cell via different
pattern recognition receptors (PRR) including the Toll-like receptors (TLRs) and the
Retinoic acid-inducible gene (RIG)-1 like receptors (RLRs) to initiate a cellular defense
[37]. The interferon (IFN) signaling pathway, unfolded protein response (UPR), DNA
repair mechanism, autophagy, and apoptosis are major cellular mechanistic defenses that
can suppress viral replication and salvage the infected host cell [35, 38-40]. While it is still
unclear how ZIKV elicits its pathogenicity related to neurodegeneration and
neurodevelopmental disorders, studies have unraveled several potential avenues that may
be involved in ZIKV pathogenesis.
1.4.1. ZIKV and the Endoplasmic Reticulum (ER) pathways
The ER provides a membrane platform for the biogenesis of flavivirus replication
complexes. Flavivirus infection leads to rearrangement of the ER membrane to form an
organelle-like structure which provides an environment for viral replication. Viral proteins
including structural and nonstructural proteins accumulated in the ER membrane facilitate
the rearrangement by changing protein and lipid content of the ER membrane [41, 42]. The
hydrophilic transmembrane viral proteins, NS4A and NS4B, are primarily involved in
membrane remodeling [43, 44]. Membrane remodeling results in the formation of the socalled vesicle pockets or double membrane vesicles (DMVs) that facilitates the assembly
of newly synthesized viral components and complete the virion packaging before
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trafficking to the Golgi complex. Therefore, interactions between the ER and flavivirus
play a key role in providing a replication platform and assembly site [45].
On the other hand, synthesis of excessive viral protein may lead to ER stress. The
intracellular signaling pathway referred to as the unfolded protein response (UPR) pathway
next comes into the scene to alleviate the ER stress. The UPR pathway is a homeostatic
signaling pathway that is activated to counteract ER stress by transcriptional induction of
genes, retardation of global protein synthesis and ER-associated degradation [46, 47]. UPR
is induced via either of three arms or stress sensors; protein kinase RNA-like ER kinase
(PERK), inositol-requiring protein 1α (IRE1α) and activating transcription factor 6
(ATF6) [46]. UPR mitigates unfolded protein load by pro-survival mechanisms such as
ER membrane expansion, decreased influx of proteins into ER, induction of
transcription of key components of protein folding. If stress is not under control, then
UPR induces selective autophagic degradation of ER (ER-phagy) or apoptosis [46].
ZIKV has been reported to induce the UPR pathway (as shown by upregulation of UPR
related genes expression) in human fetal brain cortex, mouse embryonic brain and in
vitro hNSCs. Interestingly, a pharmacological inhibitor of PERK (GSK2656157)
reverted ZIKV-mediated impairment of neurogenesis and microcephaly-like syndromes
in mouse embryos. Similarly, ZIKV associated neurogenic defects were rescued by
inhibition of PERK, whereas ZIKV replication was reduced by IRE-1α inhibitor in
cortical cells [48].
ER Stress can also lead to the formation of stress granules (SGs) by phosphorylation
of the eukaryotic initiation factor 2α (eIF2α). SGs are dynamic cytoplasmic granules
composed of cellular mRNAs and stalled pre-initiation complexes. SGs play an important
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role in maintaining RNA homeostasis under stress conditions [49]. SGs restrict viral
replication by hiding cellular translational machinery. However, some viruses can
counteract the defense mechanism provided by SGs assembly [50, 51]. In fact, ZIKV has
evolved a similar strategy to suppress SGs assembly despite activating UPR and
phosphorylating eIF2α leading to a global translational arrest. ZIKV proteins NS3 and
NS4A are involved in the translational arrest, whereas, capsid, NS3, NS2B, and NS4A cooperatively suppress SGs formation [52, 53]. However, the precise mechanism of ZIKVinduced suppression of SGs formation is still unclear.
1.4.2. ZIKV pathogenesis and host immune response
Before the recent outbreaks, ZIKV infection was considered an asymptomatic or mild
self-limiting febrile illness resolving within a few days. A wide range of tissue tropism,
multiple routes of transmission and association with severe disease involving multi-organs
are reported in the recent ZIKV outbreaks [54]. Though ZIKV is thought to be less
neurotropic than other neurotropic flaviviruses, the alarming consequence of ZIKV is its
tropism for brain cells, particularly neural progenitor cells leading to impairment of brain
growth that may result in microcephaly and other neurological disorders [54]. ZIKV is
capable of infecting almost all cell types in brain or CNS including astrocytes, microglia
[28, 55], brain microvascular endothelial cells [56], pericytes [57], oligodendrocytes and
neurons [58]. ZIKV can also infect the eye including the cornea and the optic nerves
causing uveitis and even blindness [59].
ZIKV is reported to modulate both the innate and the adaptive immune-branches of the
host defense mechanism; however, both branches may not be required to prevent the
disease [60]. The innate immune response is the primary host response that controls ZIKV

9

infection and related pathogenesis. Type 1 IFN which includes the isoforms of IFN-α, IFNβ and other minor classes (such as IFN-ε, IFN-k, IFN-ω) are crucial for antiviral response
and are produced by almost all cells in the body [61]. The expression of type I IFN is
regulated by an intracellular signaling pathway triggered by recognition of specific viral
components such as viral double-stranded (ds) or single-stranded (ss) RNA or the
replication intermediate of viral RNA by germline-encoded PRRs [37]. ZIKV induces
TLRs (mainly TLR3), RIG-1, melanoma differentiation associated protein 5 (MDA5), the
interferon-stimulated genes (ISGs) such as 2’-5’ oligoadenylate synthetase 2 (OAS2),
ISG15, and Mx dynamin-like GTPase-1 (MX1) along with IFN-β in various cell type [35].
The primary role of the innate immune response in controlling ZIKV infection is further
supported by the finding that immuno-compromised individuals or animal models are more
susceptible to ZIKV infection as well as the progression to overt disease [62]. Ifnar1−/− mice
are susceptible to ZIKV infection up to six months of age and even the younger mice within
the age of 3 weeks can succumb to overt illness [63].
However, in type 1 IFN deficient animal models, the adaptive immune response
becomes critical [60, 62]. ZIKV specific antibodies are reported to play a crucial role in
controlling viral replication in the mouse model. Anti-ZIKV antibodies with variable
neutralizing potency have been reported from the ZIKV infected patients. Interestingly,
high neutralizing responses to ZIKV were associated with pre-existing DENV reactivity,
suggesting possible cross neutralization among the members of flavivirus [64]. The
envelope (E), pre-membrane (prM) and NS1 proteins are the major targets for ZIKV
specific antibodies and therefore, are the attractive components for DNA vaccine [65].
ZIKV-induced T-cell response was studied in immunocompetent C57BL/6 mice by
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tracking surrogate markers expressed by these cells. ZIKV sensitized CD4+ T cells
polarized to a Th1 phenotype while CD8+ T-cells differentiated into the activated effector
phenotype, leading to the production of cytokines and cytolytic molecules [66]. This novel
ZIKV specific CD8+ T cell epitope identified for the envelope protein and recognized by
many cells can pave the way for the design of tetramers to study epitope-specific T cell
responses and development of ZIKV vaccine strategies [66]. Depletions of T cells resulted
in a decrease in body weight in ZIKV infected mice [67]. Interestingly, the pregnant
C57BL/6 mice are reported to be more responsive to ZIKV-induced diminutions of cellmediated immunity, leading to more viral replication and possible spread of the virus from
mother to fetus [67].
For ZIKV to evade and antagonize the host immune responses, the virus may have
evolved multiple mechanisms. The nonstructural (NS) proteins, for example, can act as an
immune response antagonist. First, ZIKV NS5 protein targets the proteasomal degradation
of STAT2, leading to inhibition of type I IFN signaling [68]. The viral proteins, NS1 and
NS4B, inhibit RLR-induced IFN-β activation at the Tank-binding kinase 1 (TBK1) level,
a multifunctional protein implicated not only in the innate immunity but also in apoptosis
and cell proliferation. Activations of STAT6 transcription factor and interferon regulatory
factor (IRF)-3 are mediated by TBK1 [60]. ZIKV infection disrupts TBK1 relocation from
the centrosome to the mitochondria which may lead to impaired mitosis and cell division
[69], suggesting TBK1 is one of the major targets of ZIKV infection [60]. The other viral
protein NS2B in conjunction with NS3 promotes the degradation of Janus kinase (JAK1)
and the inhibition of the JAK-STAT signaling, followed by inhibition of viral-induced
apoptosis and increased viral replication. Finally, NS1 and NS4B inhibit the expression of
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Type 1 IFN and consequently the degradation of NS2B and NS3 by the autophagy pathway
with subsequent suppression of viral replication by this pathway. These findings suggest
that the non-structural proteins act synergistically to restrict host antiviral responses and
facilitate viral replication [70].
1.4.3. ZIKV and the Toll-Like Receptor-3 (TLR-3) signaling pathway
The TLR3 signaling pathway is a part of the innate immune response and creates an
antiviral state in the viral-infected cell. Normally, activation of TLR3 leads to downstream
signaling pathway which involves the recruitment of TIR domain-containing adaptor
inducing IFN-β (TRIF) and subsequent activation of transcription factors such as interferon
regulatory factors (IRF)-3, IRF7 and nuclear factor kappa B (NF-κB) ultimately inducing
the production of type 1 and type 2 IFN, pro-inflammatory cytokines, chemokines and
ISGs [71, 72]. Though the role of TLR3 in ZIKV pathogenesis is still under investigation,
findings with DENV and WNV are not consistent either [73-75]. TLR3 deficient mice
(TLR3−/−) are reported to be resistant to infection with the WNV [73] and the influenza
virus [76]. Similarly, TLR3−/− mice infected with WNV showed reduced viral load in the
brain, low levels of inflammatory molecules and less prominent neuropathology when
compared to wild type mice, further suggesting the potential role of TLR3 in viral entry
into brain and neuropathology [73]. Conversely, a protective role of TLR3 with WNV
infection has also been reported shedding doubt on the exact role of TLR3 in flavivirus
pathogenesis [75]. In a separate study, activation of TLR3 was reported to block DENV
type 2 replication via induction of IFN-β in human hepatoma cell line [74].
It is consistently reported that TLR3 was activated by ZIKV possibly by sensing the
replication intermediate of viral RNA [35, 38]. TLR3 was shown to be activated by ZIKV
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in human organoid cells and murine neurospheres, causing perturbation of 41 genes
related to neurodevelopment and reducing the organoid volume as seen in clinical
microcephaly [38]. The reduction in the organoid volume was correlated with the viral
titers, indicating that activated TLR3 enhances ZIKV replication. Inhibition of
TLR3/dsRNA by a competitive inhibitor (thiophenecarboxamidopropionate) resulted in
a reversal of these phenotypic effects, while treatment with TLR3 agonist (poly I: C)
mimicked ZIKV infection in terms of brain organoid volume [38]. It is paradoxical that
a component of the innate immune response enhances viral replication and related
pathogenesis. A proposed mechanism for ZIKV induced microcephaly suggested that
ZIKV infection leads to TLR3 mediated hyper-activation of the innate immune response,
which in turn cause transcriptional deregulation of the genes related to neurogenesis
resulting in impaired neurogenesis [77].
1.4.4. ZIKV and the autophagy pathway
Autophagy mediates the lysosomal degradation of long-lived proteins, cellular
organelles and intracellular pathogens [78]. The pathway is induced by nutrient
deprivation or stress and promotes energy conservation and cell survival during
starvation by recycling and salvage of cellular nutrients. Autophagy is a complex
process involving more than 30 autophagy-related proteins (ATG) [79], crucial for
cellular development and differentiation [80], innate and adaptive immunity [81, 82],
and programmed cell death (type II) [83, 84]. Autophagosome formation involves
initiation, nucleation, and expansion of the isolation membrane [85] and begins with the
formation of the phagophore assembly site (PAS), the origin of which is still unclear in
mammals [86, 87] (Figure 3). The autophagosome fuses with endocytic and lysosomal
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compartments to form auto-endosome or autolysosome for subsequent degradation [85].
Many signaling molecules such as mammalian target of rapamycin complex 1
(mTORC1), AMP-activated protein kinase (AMPK), death-associated protein kinase
(DAPK), c-Jun N terminal kinase (JNK), Akt or protein kinase B (PKB), Casein kinase
2 (CK2), Insulin-like growth factor (IGF-1), DNA damage-regulated autophagy
modulator (DRAM), p53, Forkhead box O (FOXO) and reactive oxygen species (ROS)
are involved in autophagy regulation at various points [79].

Figure 3. The major steps in the autophagy pathway.
The major steps in the autophagy pathway. The process of autophagy induction starts
with the formation of UNC-51-like (ULK) complex comprising ULK-1, ATG13,
ATG101, and FIP200. Beclin1 dependent enzymatic activity of a phosphatidylinositol
3-phosphate kinase 34 (VPS34) generates the phosphatidylinositol 3-phosphate, a
substrate for autophagosome formation. The microtubule-associated protein light chain
3 (LC3) is cleaved and conjugated to phosphatidylethanolamine (PE) by sequencing
action of AT4B, ATG3 and ATG12-ATG5 complex and is localized to the phagophore
to facilitate autophagosome formation. P62, an adaptor protein also known as
sequestosome 1(SQSTM1), targets specific cargoes towards autophagosome. Finally,
the autophagosome fuses with the lysosome for the degradation of the cargoes.
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Microtubule-associated protein light chain-3 (LC3) and sequestosome-1
(SQSTM1, also called p62) are two important markers of autophagosome formation and
its maturation [88, 89]. During autophagosome formation, the cytosolic form of LC3 (LC3I) conjugates with phosphatidylethanolamine to form LC3-II. The lipidated form (LC3-II)
is recruited to the autophagosome and gets degraded upon fusion with the lysosome in
autolysosome, along with other damaged cellular components [88]. Induction of autophagy
as determined by conversion of LC3-I to LC3-II and formation of LC3 punctate was
recorded in fetal neuroprogenitor cells (fNSCs) infected with strains of ZIKV (MR766 and
IbH30656) in presence or absence of the lysosome inhibitor, bafilomycin A1 (Baf A1).
p62/SQSTM1 is a ubiquitin-binding protein serving as an adaptor for the autophagy
pathway by facilitating the delivery of cargo to autophagosomes [89]. A decrease in the
p62/SQSTM1 levels with ZIKV infection was reported in fNSCs, indicating that autophagy
maturation and lysosomal fusion were most likely not impaired.
On the other hand, inhibiting the autophagy pathway with pharmacological
inhibitors 3-methyladenine (3-MA) or chloroquine in both fNSCs and HeLa cells or gene
silencing targeting the autophagy-related gene (ATG)-3 in ZIKV-infected mouse embryo
fibroblast (MEF) cells resulted in a staggering decrease in viral replication. Similar results
were reported in siRNA-mediated inhibition of ATG-5 in MEF cells and siRNA-mediated
inhibition of ATG-3 and ATG-13 in fNSCs [40], while induction of autophagy with
rapamycin promoted ZIKV replication in both fNSCs and HeLa cells. These findings
present sustainable evidence that ZIKV infection induces autophagy in fNSCs, which in
turn leads to increased ZIKV replication and viral load [40]. Transient or stable expression
of the NS4A and NS4B proteins in HeLa and fNPCs significantly induced the autophagy
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pathway, potentially through inhibition of the Akt-mTOR signaling pathway [40]. Studies
have also shown that autophagy-related proteins play a significant role in placental defense
against pathogenic microorganisms [90, 91].
Although the exact mechanisms by which ZIKV crosses the placental barrier is still
not clear, it is speculated that ZIKV-packaged exosomes derived from trophoblastic cells
may mediate placental transfer. This process is similar to secretory or unconventional
autophagy, in which viral polypeptides that lack N-terminal peptides are unable to be
secreted from the ER to the Golgi secretory pathway and are instead exported via secretory
autophagy pathway [92]. Exosomes derived from ZIKV infected HEK293 cells show colocalization of the viral protein NS1 with the exosome markers CD63 and CD9,
demonstrating that NS1 is present in the exosome. Exosomes derived from HEK293 cells
transfected with NS1 plasmids further validated the presence of NS1 in exosomes. As with
the vesicular stomatitis virus (VSV), placenta-specific microRNAs packaged in exosomes
secreted from human syncytium may also induce the autophagy pathway and modulate
ZIKV replication [93]. LC3-II protein expression was significantly upregulated at 6 and 12
hours-post-infection with ZIKV in human cytotrophoblast cells and further enhanced with
Baf A1 [91]. Treatment with the pharmacological inhibitors of autophagy (3-MA,
chloroquine, and Baf A1) resulted in a significant decrease in ZIKV replication. The
autophagy inducers, rapamycin and torin 1 caused a reciprocal increase in viral replication
[91]. Mice deficient for the autophagy-related gene Atg16L1 infected with ZIKV showed
improved fetal outcomes while treatment with hydroxychloroquine in pregnant dams
caused reduced ZIKV vertical transmission and limited placental damage and fetal death
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[90]. Overall evidence support that the autophagy plays a crucial role in ZIKV replication
and vertical transmission and can be targeted for therapeutic interventions against ZIKV.
1.5.

ZIKV animal research model and challenges
So far several animal models have been proposed for ZIKV infection, including

immunocompetent mice (C57BL/6), mice lacking the receptors for interferon, mice
neutralized with the IFNAR1 antibodies, mice lacking IRF3/5/7, immunocompetent nonhuman primates and chicken embryos [94] and [95]. The most commonly employed mice
models are the A129 strain which lacks the receptors for type 1 interferon and the AG129
strain which lacks the receptors for both type 1 and 2 IFN [96-98]. Comparable results can
be achieved when using C57BL/6 mice treated with IFNAR1 monoclonal antibody before
and during viral infection or using Irf3-/- Irf5-/- Irf7-/- triple knockout mice [25, 96]. Despite
many advances in using ZIKV-infected mouse model in establishing the cell tropism, viral
replication kinetics, host immune response, teratogenicity, and clinical manifestation,
limited progress toward vaccine development has been made [95, 99]. Structural and
immunological dissimilarities between human and mice placenta, resistance of
immunocompetent mice to ZIKV replication, skepticism about the relevance of data
generated from immune compromised or genetically modified mice, limited availability of
non-human primates and associated high cost are some of the limitations that are currently
manifesting with the use of animal models [94].
1.6.

Vaccine and therapy development approach for ZIKV
Multiple vaccine platforms and approaches are being employed for ZIKV including

DNA vaccines, subunit vaccines, whole inactivated virus vaccines and vectored vaccines
[100]. The nucleoside-modified mRNA encoding the pre-membrane and envelope (prM-
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E) glycoproteins encapsulated in lipid nanoparticle (mRNA-LNP) and ZIKV prM/E
sequence DNA vaccine demonstrated robust protection against ZIKV by eliciting strong
neutralizing antibody responses both in mice and non-human primates [99, 101]. Some
DNA vaccines are currently entering phase I clinical trial or clinical evaluation [102, 103].
Some of the current approaches under evaluation are targeting viral proteins including, the
envelope protein to block cellular entry and fusion, the NS5 protein to inhibit its RNAdependent RNA polymerase and methyltransferase activities and the NS3 protein to inhibit
protease and helicase activity [104-106]. Repurposing therapy including the use of
sofosbuvir, kitasamycin, lovastatin-azauridine, palonosetron, and 5-fluorouracil are some
potential drugs under consideration for ZIKV treatment [107-109]. Another approach for
developing ZIKV treatment and vaccines is to target host cellular molecules that are
associated with increased viral replication and viral-induced inflammation. Many of the
putative molecular targets identified include AXL, TLR3, small inducible cytokine B10
(IP10), interferon-stimulated genes, IL-6 (Interleukin-6) and Eukaryotic translation
initiation factor (eIF)-2A protein kinase (eIF2AK2) [110]. Targeted immunotherapy
designed to boost the natural defenses against the pathogens can also combat ZIKV
infection and associated complications. Monoclonal antibodies against various epitopes of
ZIKV structural proteins, isolated from B lymphocytes of infected human or animals have
shown potent neutralizing activity against ZIKV [111]. Cytotoxic T lymphocytes (CD8+)
from infected mice also offer protection against ZIKV and prevent pathogenesis of ZIKV
infection [112]. The finding that ZIKV inhibits interferon signaling by targeting human
STAT2 challenges the therapeutic implication of interferons as the inhibitors of ZIKV
replication [68, 113].
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1.7.

Overview of neuron and glial cells

The main cell types in the brain are neurons and glial cells. A neuron consists of a cell
body, an axon, and many dendrites. Neurons are the core components and the basic
functional units of the brain. The microtubule associated protein 2 (MAP-2), neuronspecific enolase (NSE) and calbindin are some of the molecular markers of the neuron
[114]. Glial cells, the supporting cells in the brain, are of three types, astrocytes,
oligodendrocytes and microglia. Astrocytes are the major cell types with star-shaped
morphology and expression of intermediated filament glial fibrillary acidic proteins
(GFAP). Astrocytes are involved a multitude of functions including in supporting neurons,
support endothelial cells forming BBB, reinforcing synapses, mechanical repair, and
scarring of the brain, etc. Oligodendrocytes form the myelin sheath of the neuronal axon
in CNS analogous to Schwan cells in the peripheral nervous system. Microglia are the
resident macrophages in the brain generally remain immunologically inactive called
ramified state. Various neuroinflammatory diseases, proinflammatory cytokines, and
physical injuries can trigger microglial activation. Activated microglia can act as antigenpresenting, cytotoxic and phagocytic cells [115]. The interactions between neurons and
glial cells are depicted in Figure 4.
Mammalian CNS is developed from the neural tube containing neural stem cells
(NSCs). Early NSCs are called neuroepithelial cells, which differentiate into radial glial
cells (RGCs) with an elongated radial shape. The RGCs, which reside in the embryonic
ventricular zone, are the principal stem cells for neuronal development. RGCs are
differentiated into neurons via the intermediate step of neuronal precursor cells [116]. Thus
formed neurons migrate towards their destinations such as a cortical plate to form cerebral
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cortex, followed by generating neural circuity with axons and dendrites. Mouse cortical
neurogenesis generally takes place between embryonic day (E.D.) 11 to17. Gliogenesis,
the process of generation of glial cells generally follows neurogenesis in the fetal brain
through the differentiation of RGCs into radial glia progenitors (RGPs) [117].
Neurogenesis is almost complete before birth with negligible production of neurons from
post-natal NSCs. However, glial genesis and generation of neuronal processes continue
until adulthood, increasing the brain volume [118].

Figure 4. Interactions between cells of the central nervous system.
Adapted from Parkinson’s news today 17.
1.8.

Statement of the problem and objective of the study
The first cases of ZIKV infection in the Americas occurred in Brazil in 2015, and

since then an estimated 440,000 to 1,300,000 ZIKV infections are reported [119]. The virus
has spread throughout South and Central Americas, including the Caribbean Islands, Puerto
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Rico and the southern part of the US [120]. Increased cases of fetal malformations such as
spontaneous abortion, stillbirth, hydrocephaly, and microcephaly, and placental
insufficiency to miscarriage, now collectively known as congenital Zika syndrome (CZS),
were detected in Brazilian pregnant mothers infected with ZIKV during gestation [119].
Because of the size of the outbreak and severity of associated congenital defects, the World
Health Organization (WHO) declared ZIKV to be a Public Health Emergency of
International Concern (PHEIC) in February 2016. Though ZIKV is no more the PHEIC,
many aspects of ZIKV infection and associated pathogenesis remain to be explored to
develop effective vaccine and treatment strategies.
Mechanism of Zika viral entry into the target cell and transmission from mother to
fetus is still not clear. Confirmation of the mechanism of viral entry will pave the way for
a therapeutic target for ZIKV. Since many viruses including flaviviruses subvert autophagy
to promote different stages of the viral life cycle [121], modulation of autophagy or Beclin1
protein could be an alternative approach for ZIKV therapy. Likewise, TLR3, a key
modulator of the innate immune response against RNA viruses, could be another attractive
target for developing a therapy against flaviviruses [73, 122]. To our knowledge, this is the
first report that compares the glial-pathogenesis along with the molecular mechanism
among three spatiotemporally different ZIKV strains in the brain. The current study is
designated to explore the molecular mechanism involved in ZIKV infection and at the same
time compare the infection, pathology, and mechanism associated with spatiotemporally
different ZIKV strains. To these ends, we proposed the following specific aims:
Specific Aim 1: Determine the infectivity and the mechanism of ZIKV entry into the brain
cells.
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Specific Aim 2: Examine the molecular mechanism(s) of ZIKV infection and associated
inflammatory responses in vitro focusing on ER stress, TLR and autophagy
pathways.
Specific Aim 3: Explore the molecular mechanism of ZIKV infection and associated
obstruction in brain development using an infectious mouse model.
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CHAPTER 2: ZIKV INFECTION IN BRAIN CELLS INDUCES INFLAMMATORY
MOLECULES SECRETION AND CELL DEATH
2.1. Introduction
A

causal

association

of

ZIKV

with

severe

neurodevelopmental

and

neurodegenerative disorders prompted the scientific community to investigate the
mechanism of ZIKV-induced neuropathogenesis [1, 2]. However, most of the studies are
focusing on the direct impact of ZIKV on the neuroprogenitor cells, and the potential role
of differentiated neurons and glial cells in ZIKV-induced neuropathologies is overlooked
[3, 4]. Glial cells including astrocytes and microglia are the most important targets for
ZIKV pathology in the brain [5, 6]. Astrocytes, the most abundant glial cells are located
in the vicinity of capillaries and are a key component of the blood-brain barrier (BBB).
Therefore, astrocytes may be the first target encountered by ZIKV immediately after
entering the central nervous system. Microglia, the resident macrophages in the central
nervous system (CNS), have an important role in neuronal development and homeostasis
[7]. Glial cell infection by ZIKV may cause neuroinflammation by releasing proinflammatory molecules which lead to BBB leakage and further exacerbation of the
pathogenesis [8]. Despite the crucial role of astrocytes and microglia in ZIKV infection,
little is known about the interaction of ZIKV with the glial in terms of viral kinetics,
inflammatory profiles and cellular toxicity [5, 6].
Genetic and phylogenetic studies reveal that ZIKV has evolved into different
lineages including the African lineage comprising of the West African (Nigerian) and the
East African (MR766 prototype) clusters, and the Asian lineage including Polynesian and
Brazilian clusters [9, 10]. Genetic changes among the ZIKV lineage strains may attribute
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to the global spread of a new phenotype and the emergence of more neuro-virulent strains
[10]. Comparative studies of different ZIKV strains have shown inconsistent reports in
terms of viral lethality, cellular infectivity, antiviral responses and genetic changes [3, 1013].
The goal of the studies proposed in Aim 1 was to compare the infectivity levels of
spatiotemporally different strains of ZIKV in different brain cells and associated
neuropathology. We also investigated the viral replication kinetics and inflammatory
molecules secretion profiles. Here we report that ZIKV infects major cell types in the
CNS including neurons, astrocytes, and microglia. Our findings show that viral strains
vary in their capacity to infect these cells, to cause cell death and to induce a release of
inflammatory molecules.
2.2. Materials and methods
2.2.1. Zika virus propagation and isolation
Zika virus strains MR766 (Cat. VR84, ATCC, Manassas, VA, USA), R103451
(Cat. VR-1848, ATCC, Manassas, VA, USA) and PRVABC59 (Cat. VR-1843, ATCC,
Manassas, VA, USA) were each propagated in Vero cells (Cat. CRL-1586, ATCC,
Manassas, VA, USA) and/or mosquito cell line C6/36 (Cat. CRL-1660, ATCC, Manassas,
VA, USA). Briefly, Vero cells or C6/36 cells were grown in T75 flasks with recommended
growth media (EMEM supplemented with 10% FBS and 1% antibiotic/antimycotic
solution) to > 80% confluency and infected with 4 ml of ZIKV (diluted in EMEM) at a
multiplicity of infection (MOI) of 0.01. Culture flasks were incubated at 37°C and 5% CO2
for 2 hours with gentle rocking every 15 minutes, followed by addition of 4 ml of media
and continuous incubation for 5 days. The supernatant was harvested after 5 days,
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centrifuged and filtered using 0.45-micron filter and aliquoted in 2.0 ml cryotubes [14].
Virus titer was determined by standard plaque assay and further amplified by propagating
in C6/36 mosquito cells cultured in EMEM supplemented with 10% FBS at 28°C and 5%
CO2.
2.2.2. Viral quantification by plaque assay
Vero cells were infected with a ten-fold dilution of ZIKV stock or the supernatants
from infected/treated cells for 1 hour to allow adsorption and then washed with phosphate
buffer saline (PBS). Cells were overlaid with culture media (EMEM supplemented with
2% FBS) containing an equal volume of 3.2% carboxymethylcellulose (CMC) and
incubated for 5 days at 370C. Cells were fixed and stained with 1% crystal violet solution
prepared in 20% formaldehyde, 30% ethanol and 50% PBS for 1 hour. Stained cells were
washed with water to remove excess crystal violet, left to dry overnight, and the lysis
plaques were quantified by stereomicroscope (Figure 5A and B).
2.2.3. Cell cultures and ZIKV infection
Human primary astrocytes (Cat. 1800, ScienCell, Carlsbad, CA, USA) were grown
and maintained in astrocyte medium supplemented with 2% FBS, 1% astrocyte growth
supplement (AGS) and 1% antibiotic/antimycotic (penicillin/streptomycin (P/S)) solution
(ScienCell, Carlsbad, CA, USA). Human microglia cell line (HMC3) was purchased from
ATCC (CRL-3304) and grown in EMEM supplemented with 10% heat-inactivated FBS,
1% P/S solution. Each viral stock was diluted in the appropriate media based on cell types
to prepare an infection dose. Infection does, or the MOI was determined from the number
of cells to be infected and titer of viral stocks. As higher viral dose had toxic effects on the
primary cells, an MOI of 0.1 was used for all studies unless mentioned otherwise.
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2.2.4. Immunocytochemistry
Viral infectivity with each viral strain was measured by fluorescent
immunolabeling. Briefly, cells were fixed in 4% paraformaldehyde, permeabilized with
0.1% Triton X-100, and blocked in 10% milk/0.1% goat serum. The fixed cells were
immunolabeled using a rabbit anti-ZIKV-E antibody (Cat. GTX133314, Genetex, Irvine,
CA, USA). Immunoreactivity was visualized with secondary antibodies from molecular
probes (Carlsbad, CA, USA). 4′,6-diamidino-2-phenylindole (DAPI) was used to label cell
nuclei. The Images were analyzed using an inverted fluorescence microscope with a 560
Axiovision camera (Zeiss, Germany) (Fig. 3C). The purity of the cells was determined
immunofluorescent staining for cell-specific marker; glial fibrillary acidic protein (GFAP)
for astrocytes (Cat. MAB360, Millipore, Boston, MA, USA), ionized calcium binding
adaptor molecules 1 (Iba1) for microglia (Cat. 016-20001, FUJIFILM Wako pure chemical
corp, USA) and microtubule-associated protein 2 (MAP2) for neurons (Cat.MAB378,
Millipore, Boston, MA, USA).
2.2.5. Assessment of cell viability
Glial cell viability was determined by trypan blue dye exclusion method. Briefly,
cells were harvested using enzyme-free cell dissociation buffer at the indicated time point.
After gentle centrifugation, the resulting cell pellets were re-suspended in respective
culture media. An equal volume of 0.40% trypan blue dye (Cat. 145-0013, Bio-Rad,
Hercules, CA, USA) was added to each cell suspension. The total number of viable and
nonviable cells were counted using a TC20 automated cell counter (Bio-Rad, Hercules,
CA, USA). Cell viability was expressed as percentages of viable cells out of total cells.
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For the assessment of neuronal viability, time-lapse digital images of neurons
were recorded using an inverted microscope with an automated computer-controlled stage
encoder and environmental chamber (37 °C, 95% humidity, 5% CO2) (Zeiss) that allowed
repeated tracking of individual neurons per treatment over time. Neuronal death was
considered to have occurred upon collapse and fragmentation of the cell body. The viability
of neurons was also assessed using a live/dead cell fluorescence assay which combines
fluorescent reagents to yield two-color discrimination of the population of live cells
indicated by green fluorescence from the dead-cell population indicated by red
fluorescence (ScienCell Research Laboratories). Cells were imaged using an inverted
fluorescence microscope (Zeiss, Germany) and viable cells were manually quantified and
reported as percent of viability.
2.2.6. Inflammation and growth factor antibody array
Expression profiles of inflammatory molecules and growth factors were screened by
human inflammation antibody array C3 and human growth factor antibody array C1 (Ray
Biotech, GA, USA), respectively using cell culture supernatant from human astrocytes and
microglia infected with different strains of ZIKV. Briefly, antibody array membranes were
incubated with sample for overnight at 40C, followed by biotinylation and streptavidin
labeling. Chemiluminescence signals were detected by a ChemiDoc imaging system (BioRad, Hercules, CA, USA).
2.2.7. Enzyme-linked immune-sorbent assay (ELISA)
Secretion of interleukin (IL)-6 and -8, regulated on activation normal T cell
expressed and secreted (RANTES), monocyte chemoattractant protein 1 (MCP-1), IP10/CXCL10 and interferon beta (IFN-β) were measured in culture supernatants of human
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astrocytes infected with three different strains of ZIKV (MR766, R103451 and
PRVABC59) for different time points (24, 48,72 and 96 hours) by ELISA (RANTES Cat.
DY278-05, MCP-1 Cat. DY279-05, IL-8 Cat. DY208-05, IL-6 Cat. DY206-05 and IFN-β
Cat. 41410-1, R&D Systems, Minneapolis, MN, USA). The optical density (O.D.) was
read at A450 on a Synergy HTX plate reader (BioTek, Winooski, VT, USA).
2.2.8. Immunoblotting
Whole cell lysates were prepared in RIPA buffer (Thermo Scientific, Waltham,
MA, USA) supplemented with a mixture of protease and phosphatase inhibitors and
separated by SDS-PAGE for immunoblotting. Primary antibodies against ZIKV Envelope
protein (Cat. GTX133314, Genetex, Irvine, CA, USA) followed by secondary antibody
conjugated to horseradish peroxidase (Millipore, Billerica, MA, USA) were used to label
the infected cells. The immunoblots were exposed to SuperSignal West Femto Substrate
(Thermo Scientific, Waltham, MA, USA) and visualized using a ChemiDoc imaging
system (Bio-Rad, Hercules, CA, USA).
2.2.9. Statistical analysis
Results are reported as mean ± SEM of 3–6 independent experiments each
with more than three samples. Data were analyzed using one way, or two-way analysis
of variance (ANOVA) followed a Bonferroni post hoc test for multiple comparisons
(GraphPad Software, Inc., La Jolla, CA, USA). An alpha level (p-value) of < 0.05 was
considered significant.
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2.3. Results
2.3.1. Viral infectivity differs between the Asian and the African ZIKV strains in
human astrocytes
Three spatiotemporally different strains of ZIKV (MR766, R103451, and
PRVABC59) were propagated on Vero cells and mosquito cell line (C6/36) followed by
quantification using standard plaque assay (Figure 5A-C). The number of virions was
expressed as plaque forming units per milliliter (PFU/ml) and was further validated by
immunofluorescent labeling of ZIKV Env protein.

Figure 5. ZIKV propagation and quantification.
ZIKV was propagated in Vero cells and mosquito cell line (C6/36). Viral titer was
determined by using a standard plaque assay. Briefly, Vero cells grown to ≥ 90%
confluency were infected with serially diluted viral stock and the cells were overlaid with
semisolid media (with 3.2% carboxymethyl cellulose). After five days of incubation at
370C, the cells were washed and stained with 1% crystal violet to visualize the lysis plaques
(A). The number of plaque forming units (PFU) per ml of the viral stock was calculated
using the formula (B). Viral titers were validated by immunofluorescent staining with
ZIKV envelope-specific antibody (C).

ZIKV permissiveness in primary human astrocytes was determined by
immunofluorescent labeling, RT-PCR and western blot (Figure 6A-D). Human astrocytes
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were infected with either the Asian (R103451 and PRVABC59) or the African (MR766)
strains of ZIKV. Twenty-four hours post infection (hpi), infectivity was detected by
measuring the abundance of ZIKV envelope protein (Env) by immunofluorescent labeling
with anti-ZIKV Env antibody. ZIKV Env was detected in astrocytes infected with each
strain of ZIKV although the infectivity was significantly different among the strains with
the Asian strains showing higher levels of infectivity. The Asian strains showed the
infectivity of about 15-20% compared to about 10% infectivity of African strain (Figure
6A and B). Infectivity was confirmed by measuring ZIKV RNA by RT-PCR from the
cellular RNA extract, and ZIKV Env protein expression by western blot using cell lysates
from

infected

astrocytes.

Both

RNA

and

protein

analysis

confirmed

the

immunofluorescence data (Figure 6C and D). Overall, the data showed a higher level of
infection with the Asian strains (PRVABC59 and R103451) when compared to the African
strain of ZIKV in astrocytes.
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Figure 6. ZIKV infects primary human astrocytes.
ZIKV permissiveness in primary human astrocytes was determined by
immunofluorescence staining of infected cells with anti-ZIKV Env antibody (A and B),
RT-PCR for viral RNA in infected cells (C) and western blot with the cell lysate collected
from the infected cells (D). For each of the experiment, the cells were infected with ZIKV
at MOI of 0.1 for 24 hpi. Mock (PBS) infected astrocytes were used as a control. Data are
presented as mean ± SEM from 3 independent experiments and analyzed using one-way
ANOVA with Bonferroni post hoc correction. *p < 0.05 Vs MR and #p < 0.05 Vs R10.
MR: MR766, R10: R103451 and PR: PRVABC59.
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2.3.2. ZIKV productively infects human astrocytes leading to cell death
Since we detected ZIKV infection in human astrocytes, we next examined whether
the infection is the astrocytes supports viral replication of ZIKV. We measured the number
of active viral particles or virions released from the ZIKV-infected astrocytes in the
supernatants collected at 24, 48, 72 and 96 hpi by plaque assay. The highest numbers of
virions for all three strains of ZIKV were detected at 48 hpi, after which the virions were
decreased with time (Figure 7A). We detected higher numbers of intracellular viral RNA
copies with RT-PCR, when compared to the numbers of viral progenies secreted in the
supernatant, detected with plaque assay, suggesting that the number of active viral progeny
released in the supernatant might not correlate with the amount of intracellular viral RNA.
That was further evidenced by the observation that PRVABC59 strain showed significantly
higher RNA titers compared to the other two strains at 24 hpi, whereas the differences in
virions secretion as measured by plaque assay was observed only at 48 hours (Figure 6C
and D). In spite of high infectivity of astrocytes (about 10-25% with MOI of 0.1), we
detected a relatively low number of viral progeny (2-4 log10 PFU/mL) suggesting that
human astrocytes are efficiently infected but with the limited capacity to produce viral
progeny.
To determine cellular toxicity of ZIKV infection, we measured cell viability of
human astrocytes after 24, 48, 72 and 96 hpi with different strains of ZIKV. Cell viability
was significantly decreased after 48 hpi with all three strains of ZIKV, while the Puerto
Rican strain was significantly more toxic to astrocytes in comparison to the African strain
MR766 (Figure 7B).
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Figure 7. ZIKV replication kinetics and cell viability in primary human astrocytes.
Viral release from the cells was measured by plaque assay at indicated time points after
infection with MOI of 0.1 of each of the ZIKV strains (A). Cell viability was measured by
MTT and trypan blue dye exclusion methods at indicated time points (B). Mock (PBS)
infected astrocytes were used as a control. Data are presented as mean ± SEM from 3
independent experiments and analyzed using two-way ANOVA with Bonferroni post hoc
correction. *p < 0.05 Vs Control.
2.3.3. Viral infectivity of ZIKV in human microglia also differs among the strains
Since microglia are also important glial cells and resident macrophages in the
brain, we measured the infectivity, viral kinetics and cell viability of ZIKV infected human
microglia. Human microglia showed similar levels of ZIKV infectivity as astrocytes
(Figure 8A). Unlike astrocytes, the Honduran strain of ZIKV (R103451) showed the
lowest infectivity in microglia. We observed similar trends of viral kinetics results in
microglia except for those infected with MR766 strain, where the highest number of virions
was reported at 72 hpi (Figure 8B). Based on the immunofluorescent and plaque assay
data, microglia are less permissive and productive to Honduran strain compared to Uganda
and Puerto-Rican strains of ZIKV. A decrease in viability was also noted in microglia
infected with Asian and African strains of ZIKV and was commensurate with the viral
infectivity and virions released (Figure 8C).
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Figure 8. ZIKV infects primary human microglia.
ZIKV permissiveness in human microglia was determined by immunofluorescence
staining of infected cells with anti-ZIKV Env antibody (A). Viral release from the cells
was measured by plaque assay at indicated time points after infection with MOI of 0.1 of
each of the ZIKV strains (B). Cell viability was measured by MTT and trypan blue dye
exclusion methods at indicated time points (C). Mock (PBS) infected astrocytes were used
as a control. Data are presented as mean ± SEM from 3 independent experiments and
analyzed using two-way ANOVA with Bonferroni post hoc correction. *p < 0.05 Vs
control and #p < 0.05 Vs MR766.
2.3.4. ZIKV infects human primary neurons and induces cell death
Most of the current studies focus on the ZIKV infection in neuroprogenitor cells
and undifferentiated neurons. Much less is known about the ZIKV infection in the mature
differentiated neurons. Therefore, we infected mature differentiated human primary
neurons with different strains of ZIKV to examine the infectivity and the toxicity. We
showed that all three strains of ZIKV are capable of directly infecting human neurons
(Figure 9A). Neuronal viability was measured using time-lapse image analysis and
fluorescent live/dead assay (Figure 9B-D). Time-lapse image analysis of infected neurons
showed the Honduras strain (R103451) induced the highest neuronal death (around 35% at
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48 hpi) followed by Puerto-Rican strain (PRVABC59) (Figure 9B). The live-dead assay
showed significantly higher percentages (about 60%) of neuronal death with Asian strains
of ZIKV compared to neuronal death with African strain of ZIKV, which was about 30%
(Figure 9D).

Figure 9. ZIKV infects primary human neuron inducing cell death.
ZIKV permissiveness in human primary neurons was determined by immunofluorescence
staining of infected cells with anti-ZIKV Env antibody and MAP-2, a neuronal marker (A).
Cell viability was measured by analyzing the time-lapse image of the individual neurons
taken at multiple time points (B) and was further confirmed by live dead fluorescent
staining of neurons at the end of the time-lapse experiment (C and D). Mock (PBS) infected
astrocytes were used as a control. Data are presented as mean ± SEM from 3 independent
experiments and analyzed using one-way ANOVA with Bonferroni post hoc correction. *p
<0.05 Vs Control, #p < 0.05 Vs MR766.
Overall, the rate of infectivity among each viral strain of ZIKV correlated with
cell death in human astrocytes, microglia, and neurons. Puerto Rican strain (PRVABC59)
of ZIKV was more infectious and replicated more vigorously in glial cells which correlated
with more cell death, while Honduran strain showed more toxicity in neurons.
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2.3.5. Asian strains of ZIKV induce higher levels of inflammatory molecules in
human glial cells
As glial cells are the principal cell types involved in the release of neuro-inflammatory
molecules, a key marker of viral pathology in the brain, we examined changes in the
secretion of inflammatory molecules by astrocytes infected with different strains of ZIKV
(MOI of 0.1). Human inflammatory antibody array was performed using the supernatants
collected from the ZIKV infected astrocytes at 48 hpi (Figure 10A). Different
inflammatory molecules including IL-6, IL-1α, IL-4, IP-10, RANTES and transforming
growth factor β1 (TGF-β1) were induced in human astrocytes by all three strains of ZIKV.
The Puerto Rican strain (PRVABC59) had a more robust effect on the release of
inflammatory factors (Figure 10B).

Figure 10. ZIKV significantly induces secretion of inflammatory molecules in
human astrocytes.
Secretion of various inflammatory molecules by astrocytes infected with different strains
of ZIKV (MOI of 0.1) was measured by using Human inflammatory antibody array (A).
The inflammatory molecules that were highly expressed in human astrocytes and were also
induced by ZIKV are presented in figure (B). Mock (PBS) infected astrocytes were used
as a control. Data are presented as mean ± SEM from 3 independent experiments and
analyzed using one-way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs
Control.
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Figure 11. ZIKV induces key antiviral and inflammatory molecules in human
astrocytes.
ELISA was performed to quantify the secretion of IFN-β, IP-10, RANTES, IL-6 and IL-8
from the supernatants collected from the infected astrocytes at indicated time points. The
data are expressed as the fold change of control (uninfected astrocytes). Mock (PBS)
infected astrocytes were used as a control. Data are presented as mean ± SEM from 3
independent experiments and analyzed using two-way ANOVA with Bonferroni post hoc
correction. *p <0.05 Vs Control.
We confirmed our results using individual ELISA for MCP-1, RANTES, IL-8, IP10, and IL-6. Both the Asian and African strains of ZIKV induced the secretion of MCP1, RANTES, IP-10, IL-8 and IL-6 (Figure 11). Interestingly, the Puerto Rican strain
(PRVABC59) had the largest effect causing about 8-fold increase in RANTES, a 6-fold
increase in IP-10, a 1.5-fold increase in MCP-1 and a 3.5-fold increase in IL-8 and IL-6
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when compared to uninfected control. Except for IL-8, peak levels of the inflammatory
molecules were detected at 48 or 72 hpi, which correlated with the detected viral titers
(Figure 5D). The kinetics of cytokines/chemokines secretion showed that the PRVABC59
strain caused a rapid cytokine and chemokine response which decreases with time.
However, the MR766 strain induced a slower, persistent cytokine response. Since type 1
IFN is considered an indicator of early antiviral response by host cells to restrict virus
spread [15], we measured type 1 IFN levels (IFN-α and IFN-β) using ELISA and detected
secretion of IFN-β in human astrocytes infected with all three ZIKV strains (Figure 11),
whereas IFN-α was undetectable (data not shown). Although all three strains showed a
significant increase in the secretion of IFN-β levels, the Puerto Rican strain (PRVABC59)
induced more than a 12-fold increase in secretion with a peak reaching at 48 hpi (Figure
11), suggesting a more rigorous antiviral response. The sustained IFN-β response by human
astrocytes against the PRVABC59 strain of ZIKV throughout 96 hours’ correlates with the
suppression of viral titers.
In human microglia, the inflammatory antibody array shows increased secretion of
RANTES, IP-10, Il-6, MIP-1α, and MIP-1B with the PRVABC59 strain, but minor
twitches were observed with other two strains of ZIKV (Figure 12A). We further
confirmed the semi-quantitative data from the membrane-based assay with ELISA (Figure
12B-D). The ELISA data shows that IP-10 was significantly induced by MR766 and
PRVABC59 strains of ZIKV up to 72 hpi, whereas, RANTES was typically induced by
PRVABC59 strain of ZIKV up to 96 hpi. There was significant upregulation in IL-6
secretion by all three strains of ZIKV up to 72 hpi. The lowest infectivity of Honduran
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strain of ZIKV correlates with the minimal effect of the virus on the secretion of these
inflammatory molecules.

Figure 12. ZIKV induces key antiviral and inflammatory molecules in human
microglia.
Human inflammatory antibody array was performed to screen the inflammatory molecules
involved in ZIKV infection in microglia (A) ELISA was performed to quantify the
secretion of IP-10, RANTES, IL-6 and IL-8 from the supernatants collected from the
infected astrocytes at indicated time points. The data are expressed as the fold change of
control (uninfected microglia). Mock (PBS) infected astrocytes were used as a control.
Data are presented as mean ± SEM from 3 independent experiments and analyzed using
two-way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs Control.
2.3.5. ZIKV caused dysregulation of growth factor expression in human astrocytes
Since ZIKV has been linked to growth retardation and microcephaly which might be
caused by an alteration in the expression or release of growth factors, we analyzed changes
in human growth factors using an antibody array. Cell culture supernatants from human
astrocytes infected with the three different strains of ZIKV were analyzed. With the
exception of insulin-like growth factor binding protein-6 (IGFBP-6) which showed a 2fold increase in expression, minor increases in the release of the growth factors monocyte-
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colony stimulating factor (M-CSF), epidermal growth factor (EGF), basic fibroblast
growth factor (bFGF) and decreases in insulin-like growth factor-2 (IGF-2), insulin-like
growth factor binding protein 2 (IGFBP-2) and platelet-derived growth factor-AA (PDGFAA) (Figure 13) were detected in astrocytes infected with the Puerto Rican strain
(PRVABC59). Although we observed slight changes in the expression levels of several
other growth factors with both the Asian and African strains, these were not significant
(data not shown).

Figure 13. ZIKV induces minor changes in expression of growth factor in human
astrocytes as measured by using Human growth factor antibody array.
Mock (PBS) infected astrocytes were used as a control. Data are presented as mean ± SEM
from ≥3 independent experiments and analyzed using one-way ANOVA with Bonferroni
post hoc correction. *p <0.05 Vs Control.
2.4. Discussion
The association of recent ZIKV outbreaks with congenital birth defects and
neurological disorders has brought great attention to this global health problem. There is a
dire need for the development of a safe and effective vaccine against this neurotropic virus.
The mechanisms behind the neuropathologies mediated by ZIKV are still unclear. More
severe neurological consequences of ZIKV have been reported with the Asian lineage of
ZIKV, indicating differential ability between the Asian and the African lineage of ZIKV
to infect brain cells and develop neurological complications. Our study aimed to describe
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the comparative infectivity of three different strains of ZIKV and explore the profile of
neuro-inflammatory molecules induced following the infection. Based on the isolation
history, genomic sequence analysis, phylogenetic analysis and geographical distribution of
the virus, we selected three viral strains representing both Asian and African lineage of the
virus.
We reported that the Asian lineage of ZIKV, specifically the Puerto Rican strain
(PRVABC59) showed higher infection which correlated with higher levels of proinflammatory molecules secretion and increased cell death in glial cells. A recent study has
reported that Asian (ZIKV-Br) and African strains (MR766) of ZIKV are almost equally
infective to human brain cortical astrocytes inducing secretion of IP-10, IL-6, IL-8, and
RANTES [16]. Contrasting to our findings, Huang et al. observed higher infectivity with
African strain (MR766) than the Asian strain (PRVABBC59) in human fetal astrocytes
[17]. The discrepancy among these studies might be associated with the viral strains,
passage numbers, and sources of astrocytes, MOI of virus used, and other factors.
Nevertheless, all of the studies conclude that ZIKV strains differentially infect astrocytes
and induce antiviral inflammatory responses with typically higher levels of chemokines.
Glial cells have a primary role in the innate immunity in the brain by recognition of
pathogens and their clearance [18]. Here, we focused on astrocytes due to their abundance
in the brain, their direct linkage with neurons and their role in synaptic support, axonal
guidance, and involvement in the BBB [19]. Herein, we reported a significant increase in
the inflammatory molecules, RANTES, MCP-1, IP-10, IL-8 and IL-6 with ZIKV infection
in glial cells. CXCL10/IP-10, an important biomarker of severity in many infectious
diseases and anti-flaviviral response in the CNS was previously reported to be induced by
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ZIKV and other flaviviruses [20-23]. Notably, IP-10 is strongly implicated in GBS,
indicating that elevated levels of IP-10 might mediate ZIKV-mediated neuronal injury. In
this study, the Asian strains of ZIKV, specifically the Puerto Rican strain (PRVABBC59),
which is more likely to cause neurodegenerative disorders, showed a very high level (up to
6-fold) of IP-10 secretion by astrocytes. The pro-inflammatory molecules; IL-6, IL-8,
RANTES, and MCP-1, which recruit and activate other cell types to the infection site and
amplify the inflammatory cascades, were augmented by all three strains of ZIKV in
astrocytes. ZIKV induced IFN-β in general; however, the secretion levels were straindependent with the Puerto Rican strain inducing around a 14-fold increase. Although
inflammatory molecules and IFNs are secreted as a host defense mechanism to attenuate
viral burden, the high levels of inflammatory molecules secreted by brain cells may disrupt
the BBB and facilitate further spread of the virus in CNS [21, 24]. Cytokine kinetics in our
study mimics the kinetics reported in clinical cases of ZIKV where RANTES, IL-6, IP10,
and IFN-β were elevated both in acute and convalescent phases of ZIKV infection, albeit
higher levels were detected during the acute phase. On the other hand, a higher level of IL8 was detected during the convalescent phase than the acute phase of ZIKV infection.
Moreover, elevations in chemokines were more pronounced than in cytokines [25]. In line
with our study, different kinetics of anti-viral responses in astrocytes infected with Asian
(H/PF/2013) and African strain (HD78788) of ZIKV has been reported by Hamel et.al. A
more rapid antiviral response, as shown by increased expression of several inflammatory
molecules including IP-10, RANTES, IL-6, and IFN-β within 6 hpi, was induced with
Asian strains when compared to the African strain which induced delayed response [26].
Although the changes were not significant, we observed minor changes in the growth
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factors, M-SCF, IGFBP-6, IGFBP-2, IGF-2, and PDGF-AA in ZIKV infected astrocytes,
which may contribute to ZIKV associated neurodevelopmental disorders.
In our study, we reported significantly more cell death mediated by ZIKV
compared mock-infected cells. The secretion of exaggerated levels of inflammatory
molecules by glial cells might have contributed to cell death. Though type 1 IFN might be
the classical antiviral response, persistent higher levels of secreted inflammatory cytokines
and chemokines induce a pattern of acute or chronic inflammation potentially leading to
neurotoxicity. Some of the cytokines are also involved in the activation of the death
receptor facilitating the apoptosis mediated cell death besides the formation of the
inflammasome. Combined with the studies showing activation of apoptosis by ZIKV, our
data indicate that ZIKV induced inflammatory molecules secretion may lead to apoptosis
[27]. Cell death, in turn, may provoke an inflammatory response [28].
In summary, we report differences in infectivity rate and the secretion of
inflammatory molecules in human glial cells infected with three different spatiotemporal
strains of ZIKV. Excessive and persistent inflammatory responses potentially lead to
ZIKV-related cell death. The differences in infectivity levels, inflammatory responses, and
cellular toxicity may account for differential pathology in the viral strains and clinical
manifestations in affected populations.
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CHAPTER 3. MECHANISM OF ZIKA VIRUS ENTRY INTO HUMAN PRIMARY
ASTROCYTES
3.1. Introduction
ZIKV, similar to other members of the flavivirus, enters the cell presumably by
receptor-mediated endocytosis [1, 2]. The molecular mechanisms of viral entry into brain
cells and the associated pathology are still poorly understood. Discovery of the mechanism
of entry and associated factors is one of the most important aspects of viral pathogenesis
and cellular tropism. Current studies suggest that Tyro3 Axl MER (TAM) family of
receptors are shown to be the primary entry factors for ZIKV in various cell types [2, 3].
Out of the putative ZIKV receptors, Axl is the most studied receptor in regards to ZIKV
infection. Axl is a member of the TAM family of receptors that was originally cloned from
cancer cells [4]. The receptor has two ligands including the growth arrest-specific-6 (Gas6)
and the protein S [5]. Axl is involved in the innate immune response as well as other cellular
mechanisms including proliferation, migration, and aggregation in different cell types [6,
7].
Exposure to neutralizing antibody against Axl or by gene silencing using small
interfering RNA targeting the Axl gene led to a decrease in viral replication and infection,
suggesting a role of Axl as a putative ZIKV entry receptor in human fibroblast cells [8].
Human neural progenitor cells, microglia, and astrocytes isolated from developing brain
express Axl receptors. A previous study has shown that inhibition of Axl by synthetic
decoy receptor (MYD1) and Axl kinase inhibitor (R428) resulted in the inhibition of ZIKV
infection in the glial cells [2]. However, others have reported that silencing the Axl gene
was unable to inhibit viral entry but rather facilitates the upregulation of type 1 interferon
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signaling, indicating that Axl promotes ZIKV infection in glial cells by antagonizing type
I interferon (IFN) signaling. It is still unclear whether ZIKV entry and subsequent
replication are solely dependent on the Axl receptor [9-11].
The controversial reports regarding the role of TAM (Axl) receptor in ZIKV
infection in brain cells necessitate further investigation using more than one spatiotemporal
ZIKV strains and primary cells because the cell lines might not express the receptors and
may behave differently than the primary cells [10, 11]. Therefore, effective contributions
of Axl and other members of TAM receptors in ZIKV entry and pathogenesis need to be
investigated using primary brain cells. The objective of this study was to examine the role
of TAM receptors, including Axl in ZIKV infection using primary human astrocytes, the
major cell types in the brain. Herein we used genetic and pharmacological approaches to
downregulate the receptors and report that Axl receptor but not the Tyro3 receptor is
involved in ZIKV infection and replication in human astrocytes and associated antiviral
response.
3.2. Methodology
3.2.1. Cell cultures, treatment, and ZIKV infection
Human primary astrocytes (Cat. 1800, ScienCell, Carlsbad, CA, USA) were grown
and maintained in astrocyte medium supplemented with 2% FBS, 1% astrocyte growth
supplement (AGS) and 1% antibiotic/antimycotic solution (ScienCell, Carlsbad, CA,
USA). Each viral stock was diluted in the appropriate media based on cell types. Infection
dose or the MOI was determined from the number of cells to be infected and titer of viral
stocks. As higher viral dose had toxic effects on the primary cells, an MOI of 0.1 was used
for all studies unless mentioned otherwise.
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3.2.2. Immunoblotting
Whole cell lysates were prepared in RIPA buffer (Thermo Scientific, Waltham,
MA, USA) supplemented with a mixture of protease and phosphatase inhibitors and
separated by SDS-PAGE for immunoblotting. Primary antibodies against ZIKV Envelope
protein (Cat. GTX133314, Genetex, Irvine, CA, USA) followed by secondary antibody
conjugated to horseradish peroxidase (Millipore, Billerica, MA, USA) was used to label
the infected cells. The immunoblots were exposed to SuperSignal West Femto Substrate
(Thermo Scientific, Waltham, MA, USA) and visualized using a ChemiDoc imaging
system (Bio-Rad, Hercules, CA, USA).
3.2.3. RNA interference: silencing of the Axl receptor
Small interfering RNA (siRNA) Axl (Cat. sc-29769) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Human primary astrocytes were transfected with
siRNA against Axl for 24 - 48 hours using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) or Fugene HD (Promega, Madison, WI, USA) for Axl knock down. siRNA and
transfection reagent (ratio, 1:2) were pre-incubated for 20 min in OptiMEM medium before
addition to the seeded cells. Knockdown of targets was confirmed in cell lysates by western
blot for the protein expression of Axl receptor using a primary antibody against Axl (Cat.
sc-166269, Santa Cruz Biotech, USA).
3.2.4. Inhibition of Axl and Tyro3 by small molecule inhibitors
Human primary astrocytes were grown to 80-90% confluency in astrocytes-specific
media as described in chapter 2. Half an hour prior to ZIKV infection, the cells were treated
with increasing concentrations (0.1, 0.5 and 1μM) of either small molecule inhibitor of Axl
(R428, Cat.S2841) or Tyro3 inhibitor (BMS777607, cat. S1561, Selleck, USA). The
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concentration of the inhibitors was selected based on the previous literature and their
inhibitory concentration 50 (IC-50). With continuous exposure of the cells to the inhibitor,
cells were infected with ZIKV as mentioned previously.
3.2.4. Statistical analysis
Results are reported as mean ± SEM of 3–6 independent experiments each
with more than three samples. Data were analyzed using analysis of variance (ANOVA)
followed by appropriate post hoc test for multiple comparisons (GraphPad Software, Inc.,
La Jolla, CA, USA). An alpha level (p-value) of < 0.05 was considered significant.
3.3. Results
3.3.1. TAM receptors and their ligands are expressed in human astrocytes.
To determine a potential mode of viral entry in human glial cells, we investigated the
expression of putative host receptors utilized by ZIKV, as reported by others [2, 3]. Protein
expression of the receptors was assessed by immunoblotting of the cell lysate with or
without ZIKV infection. Members of the TAM receptors, Tyro3, Axl, and MERTK were
detected in human astrocytes, but surprisingly infection with any of the three ZIKV strains
had no effect on protein expression levels of Axl, although a slight increase in the
expression of Tyro3 was observed with both Asian and African strains (Figure 14). We
also investigated the expression of growth arrest- Specific protein 6 (Gas6), which bridges
the virus to the cells. Gas6 expression was also detected in human astrocytes. However,
exposure to ZIKV had no effect on its expression (Figure 14).
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Figure 14. TAM receptors and their ligand Gas6 are expressed in human astrocytes.
Protein expression of Axl, Tyro3, MERTK, and Gas6 was measured by western blot from
the lysate of human astrocytes uninfected or infected with different strains of ZIKV at MOI
of 0.1 for 24 hours. Data are presented as mean ± SEM from 3 independent experiments
and analyzed using one-way ANOVA with Bonferroni post hoc correction for multiple
comparisons. *p <0.05 Vs Control.

3.3.2. Inhibition of Axl suppresses ZIKV infection in human astrocytes
To examine the role of Axl receptor in ZIKV entry, we pre-treated human
astrocytes with a pharmacological inhibitor of Axl (R428) followed by infection with
ZIKV. After 48 hpi, ZIKV infectivity of the astrocytes was determined by immunolabeling
of ZIKV Env protein. The inhibition of host Axl receptor with R428 correlated dosedependently with a decrease in ZIKV infection (Figure 15A and B). Interestingly, we
observed a decrease in ZIKV-induced secretion of IFN-β by human astrocytes treated with
R428 (Figure 15C), which correlates with a decrease in ZIKV infection. The decrease in
IFN-β secretion might be because of the viral suppression caused by Axl inhibition or the
direct effect of Axl inhibition on downstream signaling molecules involved in the induction
of IFN secretion. We further measured the effect of Axl inhibition in the number of virions
released in the supernatants from the infected astrocytes as an indicator of viral replication.
The viral titer in the supernatants was decreased with R428 mediated inhibition of Axl in
ZIKV infected astrocytes irrespective of the viral strains. However, the inhibitory
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concentration of R428 may vary based on the strains. In fact, the Honduras strain
(R103451) of ZIKV responded only to the highest concentrations of inhibitor (1μM)
(Figure 15D). In order to determine any toxicity of R428, we examined the cell viability
of astrocytes treated with increasing concentration of the compound. The toxicity was not
detected up to the concentration of 5μM (Figure 16A).
Next, we confirmed the effect of Axl inhibition on ZIKV infection by genetically silencing
Axl by siRNA in primary human astrocytes. We found about 60% decrease in axl
expression and the transfection related toxicity was similar in siNT (Control) and siAxl
transfected cells (Figure 16A and B). We found a similar decrease in viral infection by
siRNA mediated silencing of Axl in the astrocytes (Figure 16C). Overall, the data suggest
strain-dependent differences in the extent of inhibition of ZIKV entry by TAM inhibitors
specifically Axl. Of note, some levels of infection or viral entry with all three strains were
detected even after the treatment with a high dose of R428, suggesting an involvement of
an alternative or secondary mechanism of ZIKV entry into astrocytes. Nevertheless, the
data indicate that the Axl receptor plays an important role in ZIKV infection.
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Figure 15. Inhibition of Axl by small molecule inhibitor (R428) decreases ZIKV
infection in human astrocytes.
(A and B) ZIKV infectivity was measured by immunofluorescent staining of ZIKV Env
protein in human astrocytes treated with increasing concentrations of Axl kinase inhibitor
(R428). The cells were treated with R428 30 minutes prior to infection with ZIKV and
fixed for immunostaining after 48 hours. (C) Secretion of IFN-β was measured by ELISA
from the supernatants collected from the infected astrocytes exposed to different
concentrations of R428. (D) The infectivity was further confirmed by measuring viral titers
in cell supernatants by RT-PCR. Data are presented as mean ± SEM from 3 independent
experiments and analyzed using one way or repeated measures ANOVA with Bonferroni
post hoc correction. *p <0.05 Vs Control, **p <0.005 Vs Control, and ***p <0.001 Vs
Control.
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Figure 16. Genetic silencing of Axl also decreases ZIKV infection in human
astrocytes.
Axl was knocked down by siRNA against Axl using lipofectamine 2000 transfection
reagent. (A) Validation of Axl knockdown by immunoblotting. (B) The cells (both knocked
down and parental) were infected with ZIKV at MOI of 0.1, and viral RNA titer was
determined in the supernatants collected at 48 hpi. Data are presented as mean ± SEM from
3 independent experiments and analyzed using unpaired t-test and two-way ANOVA with
Bonferroni post hoc correction. *p <0.05 Vs Control.

3.3.3. Inhibition of Axl enhances ZIKV-mediated inflammatory molecules secretion
in human astrocytes
We detected a concurrent decrease in IFN-β response with a decrease in ZIKV
infection in the astrocytes treated with R428 suggesting that the host immune response
correlates with the viral burden in the cells. To further explore the impact of Axl inhibition
on host inflammatory response, we measured IP-10 secretion by the infected cells exposed
to R428 or having Axl knockdown. The data showed that there was no significant effect of
Axl inhibition on the secretion of IP-10 by the astrocytes infected with MR766 and
R103451 strains of ZIKV. However, pharmacological and genetic inhibition of Axl in
astrocytes enhanced PRVABC59-induced secretion of IP-10 (Figure 17A and B). Since
Axl is known to control the inflammatory response in the infected cells, inhibition of Axl
may lead to exaggerated secretion of inflammatory molecules even at low viral titers as
shown by the current data.
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Figure 17. Axl antagonizes IFN response in human astrocytes.
(A) Secretion of IP-10, as a marker of IFN response, was measured by the ELISA method
from the supernatants collected from the infected astrocytes exposed to different
concentrations of R428. (B) Secretion of IP-10 was measured from the supernatants
collected from the infected astrocytes with or without siRNA mediated Axl knockdown.
Data are presented as mean ± SEM from 3 independent experiments and analyzed using
one way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs Control.

3.3.4. Inhibition of Tyro3 had no effect on ZIKV infection in human astrocytes
Since we observed significant upregulation of Tyro3 receptor expression by ZIKV,
we next inhibited Tyro3 by different concentration of c-Met specific small molecule
inhibitor (BMS777607) in human astrocytes. Inhibition of Tyro3 had no effect on ZIKV
infection in human astrocytes indicating that ZIKV cellular entry may be independent of
Tyro3 (Figure 18A). Similarly, inhibition of tyro3 had no effect on ZIKV-mediated
secretion of an inflammatory molecule, IP-10 (Figure 18B).

Figure 18. Inhibition of Tyro3 by small molecule inhibitor (BMS77607) has no effect
on ZIKV infection in human astrocytes.
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(A) ZIKV RNA titer was measured by RT-PCR in the supernatants collected from human
astrocytes treated with increasing concentrations of Tyro3 inhibitor (BMS777607). (B) IP10 was measured by ELISA from the supernatants collected from the infected astrocytes
exposed or unexposed to different concentrations of BMS777607. Data are presented as
mean ± SEM from 3 independent experiments and analyzed using one way ANOVA with
Bonferroni post hoc correction. *p <0.05 Vs Control.
3.3.5. Inhibition of Tyro3 had no additive effect on ZIKV infection in human
astrocytes treated with Axl inhibitor
ZIKV infection in human astrocytes was significantly suppressed by Axl inhibitor,
but not by Tyro3 inhibitors while using them separately. Next, we asked whether the
combination of both Axl and Tyro3 inhibitors show a synergistic effect on ZIKV infection
in human astrocytes. To this end, we treated human astrocytes with R428 and BMS777607
before infection with different strains of ZIKV. We chose the concentration of 1μM for
both of the inhibitors based on previous pieces of literature [2, 12]. ZIKV RNA copies were
measured in the supernatants collected from the infected astrocytes at 48 hpi. R428 alone
and in combination with BMS777607 reduced the viral titers by about 2 log10 copies.
However, the Tyro3 inhibitor (BMS777607) had no additive effect on ZIKV titers with
any of the viral strains (Figure 19A). We also measured the secretion of IP-10 by infected
astrocytes exposed to either or both of the inhibitors. There were no significant changes in
secretion of IP-10 with any of the inhibitors and with any of the viral strains (Figure 19B).
Overall, the data indicate that Tyro3 receptor is neither involved in ZIKV infection and
associated inflammatory molecules secretion nor backs up the Axl receptor in doing so.
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Figure 19. Inhibition of Tyro3 had no additive effect on ZIKV infection in human
astrocytes treated with Axl inhibitor.
(A) ZIKV RNA titer was measured by RT-PCR in the supernatants collected from human
astrocytes treated with both Axl and Tyro3 inhibitors at a concentration of 1μM each. (B)
IP-10 was measured by ELISA from the supernatants collected from the infected astrocytes
exposed or unexposed to Axl and Tyro3 inhibitors. Data are presented as mean ± SEM
from 3 independent experiments and analyzed using one-way ANOVA with Bonferroni
post hoc correction. *p < 0.05 Vs control.
3.3.6. Axl is necessary for ZIKV entry as well as for replication in human astrocytes
By now, it is clear that Axl receptor is involved in ZIKV infection. However,
whether Axl mediates only the viral entry into the cells or also facilitates viral replication
is still not clear. Previously, we used a single time point for the measurement of viral titers.
Therefore, in order to explore whether inhibition of Axl suppresses viral replication, we
infected human astrocytes with Axl knocked down or pretreated with Axl inhibitor and
measured viral titers at different time points, i.e., 24, 48 and 72 hpi. Here, we found that
ZIKV replication was also repressed by Axl inhibition since there was no significant
increase in viral titers with time. However, higher viral titers were detected at later time
points than the initial time point in the infected control cells (without Axl inhibition)
indicating viral replication (Figure 20A).
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Gas6 is the major Axl ligand probably facilitating the binding of ZIKV envelope
proteins with the receptor for internalization of the virus. We next examined the role of
Gas6 in ZIKV infection and replication. Since fetal bovine serum (FBS) used in culture
media naturally contains Gas6 [13], we infected human astrocytes with ZIKV
(PRVABC59) in the absence of FBS to minimize the exposure to Gas6. ZIKV infection of
the astrocytes was significantly decreased in the absence of FBS supporting the tripartite
model of ZIKV entry into the cells (Figure 20B). However, ZIKV replication was not as
drastically decreased with reduced Gas6 as with Axl inhibition. The data indicate that
though Gas6 is necessary for ZIKV entry, it may not facilitate ZIKV replication.

Figure 20. Axl facilitates ZIKV entry as well as replication within human astrocytes.
(A) ZIKV RNA titer was measured by RT-PCR in the supernatants collected at indicated
time points from infected human astrocytes untreated or treated with both Axl inhibitors at
a concentration of 1μM each or Axl silenced using siRNA against Axl. (B) ZIKV RNA
titer was measured by RT-PCR in the supernatants collected at indicated time points from
infected human astrocytes under regular growth conditions or under serum-free conditions.
Data are presented as mean ± SEM from 3 independent experiments and analyzed using
two way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs Control, **p <0.005
Vs Control.
3.4. Discussion
Because of the devastating neurodevelopmental and neurodegenerative
consequences of ZIKV infection, there is a dire need for a preventive and therapeutic
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solution. Currently, there are dozens of treatment approaches, and vaccine candidates under
the evaluation with two of them progressed to human clinical trial phase 2 [14]. However,
there is no specific treatment for the ZIKV infection yet. Most of the treatment approaches
currently being studied are focused on directly targeting viral particles. The mutability of
the viral genome, spatiotemporal heterogeneity of ZIKV transmission, the unpredictability
of ZIKV epidemics and the wide ranges of clinical manifestations are some of the
constraints for direct viral targeting approach. Therefore, we aim to identify potential host
factor therapeutic target. We first examined the protein expression of putative ZIKV
receptors, the TAM family receptors. Based on the expression pattern, we hypothesized
that targeting Axl and/or Tyro3 could be a potential approach to suppress ZIKV infection.
Herein, we report that inhibition of Axl caused a decrease in ZIKV infection.
Since several inhibitors of Axl receptors including R428 are currently in clinical trials
against cancer that could be a unique antiviral treatment for ZIKV infection. The enveloped
viruses such as DENV exploit Axl for viral entry by exposing phosphatidylserine residue
on the external surface their envelope protein. By doing so, the virus mimics an apoptotic
cell which Axl targets. The virus-mediated apoptotic mimicry allows virus not only to enter
the permissive cells but also counteract type 1 IFN responses [15]. However, there is still
a debate about whether Axl just facilitates ZIKV entry or also promote viral replication at
the later point following viral entry. R428 neither blocks the viral entry or affect cell surface
expression of Axl receptor, but significantly reduces viral titers. This supports the notion
that Axl mediates innate immune response besides the direct involvement in the viral entry
process. We further showed that targeting the Axl ligand Gas6 could be another approach
to down-regulate the Axl function. In agreement with our findings MYD1 the Axl decoy
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receptor that sequesters Gas6, also reduces ZIKV infection. Gas6 is the ligand for TAM
receptors and facilitates viral binding to Axl [2]. Previous studies have shown that Axl
antagonizes type 1 IFN signaling and promotes ZIKV infection in the infected cells [3].
Detection of similar viral titers at different time point after ZIKV infection in the Axl
inhibited astrocytes indicate that inhibition of Axl suppresses ZIKV entry as well as the
replication thereafter. Though the exact mechanism how Axl facilities viral replication is
still not clear, it has been shown that tyrosine kinase activity of the Axl is required for viral
replication [16].
Of note, we couldn’t observe the absolute suppression of the ZIKV infection even
at high concentration of Axl inhibitor indicating that an alternative mechanism of cellular
entry can’t be ruled out. Besides viral entry to particular cell types, additional mechanisms
including the ability of ZIKV to cross placental and BBB, virus-induced inflammation, the
immune response of the patients may determine the extent of neuropathological
manifestations related to ZIKV [14].
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CHAPTER 4: TLR3 REGULATES ZIKV INFECTION AND ASSOCIATED HOST
INFLAMMATORY RESPONSES IN HUMAN GLIAL CELLS
4.1. Introduction
ZIKV neurotropism and associated neurological and congenital complications have
already been established [1]. Despite the persistent effort of the scientific community, the
mechanism regulating ZIKV virus replication and associated pathologies in the brain is yet
to be understood. Being a flavivirus, ZIKV can be expected to behave similarly to other
flaviviruses. Flaviviruses exploit the ER membranes by rearranging them to form a
replication platform that facilitates the assembly of newly synthesized viral components
and complete the virions packaging before trafficking to the Golgi complex [2-4].
Synthesis of excessive viral protein in the close vicinity of the ER may, in turn, lead to ER
stress. Cellular UPR pathway, which is a homeostatic signaling pathway counteracting ER
stress mitigates unfolded protein load by pro-survival mechanisms such as ER membrane
expansion, decreased influx of proteins into ER, induction of transcription of key
components of protein folding [5, 6]. If the stress is not under control, UPR induces ERphagy or apoptosis. UPR is induced via either of three arms or stress sensors; PERK,
IRE1α and ATF6 [5]. ZIKV induces UPR pathway in human fetal brain cortex, mouse
embryonic brain and in vitro hNSCs, while PERK inhibitor rescues ZIKV associated
neurogenic defects [7]. The current understanding of the ZIKV-interaction with ER
stress and the related pathway is limited. Therefore, we aimed to investigate the role of
the UPR pathway in ZIKV infection and associated neuropathologies.
ZIKV infection in the acute and convalescent phases induces secretion of various
pro-inflammatory molecules including IP-10, RANTES and MCP-1, IL-6 [8]. We have
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already assessed the levels of inflammatory molecules induced by different strains of
ZIKV in human astrocytes and microglia. However, the exact mechanism of ZIKV
induced inflammatory molecules secretion is still not clear. Activation of the TLR
pathway and subsequent upregulation of pro-inflammatory molecules secretion by glial
cells is a key component of neuroinflammation associated with many neurological
disorders [9]. TLR pathway mediates an early innate antiviral response by inducing the
IFN signaling besides the induction of inflammatory molecules secretion [10, 11]. Since
ZIKV is reported to activate TLR3 in human organoid cells and murine neurospheres,
leading to perturbation of genes related to neurodevelopment and reducing the organoid
volume as seen in clinical microcephaly [12], we hypothesized that TLR3 pathway
might be involved in ZIKV infection and associated neuropathologies in the brain.
The goal of the specific aim 2 was to determine the mechanisms of ZIKV mediated
neuropathology specifically neuroinflammation using primary human astrocytes infected
with spatiotemporally different strains of ZIKV. Our findings showed that ZIKV induces
the UPR pathway via PERK and TLR pathway via TLR3 in human astrocytes. We further
report that the TLR3 pathway is an important player in ZIKV replication and the release of
inflammatory molecules in astrocytes, irrespective of viral strains.
4.2. Materials and methods
4.2.1. Cell cultures, treatment, and ZIKV infection
Human primary astrocytes were grown and maintained as explained in the previous
chapters. The TLR3/dsRNA complex inhibitor (a thiophenecarboxamidopropionate
compound) and TLR3 agonist (Poly I:C) were purchased from Millipore Sigma and Sigma
Aldrich, respectively. To infect with each viral strain, viral stock was diluted in the
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appropriate media based on cell types. Cells were infected with the ZIKV as in the previous
experiments.
4.2.2. mRNA expression profiling
Expression of genes involved in the UPR pathway and TLR pathway was
determined by RT-PCR profilers array. Briefly, human astrocytes were infected with three
strains of ZIKV (MR766, R103451, and PRVABC59) for 24 hours. RNA was isolated
using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Purity of the RNA (O.D.
260/280 nm absorbance ratio of at least 2.0) was measured by a microspot RNA reader
(Synergy HT Multi-Mode Microplate Reader from BioTek) and 0.5 µg of RNA was used
for cDNA synthesis using Qiagen's RT2 First Strand Kit (Cat. 330401, Qiagen, Valencia,
CA, USA) as per the manufacturer's protocol after eliminating genomic DNA. Then, the
synthesized cDNA was mixed with RT2 SYBR Green/ROX PCR master mix (Cat.
330520, Qiagen, Valencia, CA, USA) to run RT-PCR in 96 well plates according to
manufacturer’s protocol.
4.2.3. Immunoblotting
Immunoblotting was done as described in previous sections. Primary antibodies
against TLR3 (Cat. sc-28999, 1:200), TLR4 (Cat sc-30002, 1:200), TLR5 (Cat. sc-10742,
1:200), MyD88 (Cat. sc-74532, 1:200), PERK (Cat. sc-377400, 1:200), IRE1α (Cat. sc390960, 1:200), ATF6α (Cat. sc166659, 1:200), DDIT3 (Cat. sc-7351, 1:200) and β actin
(Cat. sc-47778, 1:200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were followed
by incubation with a respective secondary antibody conjugated to horseradish peroxidase
(Millipore, Billerica, MA, USA) used at specified dilution.
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4.2.4. Immunocytochemistry
Viral infectivity with each viral strain was measured by fluorescent
immunolabeling. Briefly, cells were fixed in 4% paraformaldehyde, permeabilized with
0.1% Triton X-100, and blocked in 10% milk/0.1% goat serum. Human astrocytes were
immunolabeled with mouse anti-GFAP antibody (Cat. MAB360, Millipore, Boston, MA,
USA) and rabbit anti-ZIKV-E antibody (Cat. GTX133314, Genetex, Irvine, CA, USA).
Immunoreactivity was visualized with secondary antibodies from molecular probes
(Carlsbad, CA, USA). 4′,6-diamidino-2-phenylindole (DAPI) was used to label cell nuclei.
The Images were analyzed using an inverted fluorescence microscope with a 560
Axiovision camera (Zeiss, Germany).
4.2.5. NF-κB Nuclear localization assay
Nuclear and cytoplasmic fractions were separated using fractionation buffer
(HEPES-20mM, KCL-10mM, MgCl2-2mM, EDTA-1mM, DTT-1 mM, and protease and
phosphatase inhibitor cocktail) and differential centrifugations. Both the nuclear and
cytoplasmic

NF-κB

was

measured

by

immunoblotting

as

described

above.

Immunofluorescent staining for NF-κB and GFAP was performed to locate and quantify
the nuclear and cytoplasmic NF-κB punctae. The number of NF-κB punctae within the
nuclei and outside the nuclei but within the cytoplasm were counted from at least 50 of the
40X microscopic fields selected randomly.
4.2.6. Silencing of PERK and TLR3 in human astrocytes
Human primary astrocytes were transfected with siRNA against PERK and TLR3
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) or Fugene HD (Promega,
Madison, WI, USA). siRNA and transfection reagent (ratio, 1:2) were pre-incubated for 20
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min in OptiMEM medium before addition to the seeded cells. Knockdown of targets was
confirmed in cell lysates by western blot for the protein expression of PERK and TLR3.
4.2.7. Statistical analysis
Results are reported as mean ± SEM of 3–6 independent experiments each
with more than three samples. Data were analyzed using analysis of variance (ANOVA)
followed by appropriate post hoc test for multiple comparisons (GraphPad Software, Inc.,
La Jolla, CA, USA). An alpha level (p-value) of < 0.05 was considered significant.
4.3. Results
4.3.1. ZIKV induced ER stress and unfolded protein response (UPR) pathway in
human astrocytes
Since flaviviruses including ZIKV replicate in close association with the ER and we
reasoned that ZIKV replication mediates ER stress responses that could potentially be
linked to high levels of inflammation and cell death [2], we, first, investigated ER stress
and related pathways. We measured changes in mRNA expression of genes involved in the
unfolded protein response pathway using gene expression profile arrays from RNA isolated
after infection with the different strains of ZIKV in human astrocytes. Infection with the
Asian strains (R103451 and PRVABC59) showed increased expression of the DNA
damage-inducible transcript (DDIT3) and peptidyl-prolyl cis-trans isomerase A (PPIA)
genes, while infection with the African strain caused increased expression of fork-head box
06 (FOX06), mitogen-activated protein kinase-10 (MAPK10), Insulin inducible gene 1
(INSIG1) and PPIA genes (Figure 21A). DDIT3 is a member of the CCAAT/enhancerbinding protein (C/EBP) family of a transcription factor which is activated by ER stress to
promote apoptosis. PPIA binds to unfolded proteins including viral proteins; the FOX06
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gene is involved in DNA damage and cell cycle regulation, the MAPK10 (also called Janus
kinase-3 or JNK3) gene, regulates multiple biological processes including stress-induced
neuronal apoptosis while INSIG1 regulates lipid metabolism [13-16].
The upregulated genes are mainly related to DNA damage and cell cycle regulation.
Therefore, we further measured the protein expression of representative genes involved in
DNA damage induction (DDIT3) and cell cycle regulation (MAPK10). Infection with the
Honduras strain (R103451) shows induction of protein expression of DDIT3 (Figure 21B).
We observed upregulation of the MAPK10 gene in cells infected with the African strain
(MR766), and given that MAPK signaling pathway is known to induce inflammation, we
examined the expression level of JNK, a major component of MAPK signaling, by western
blot. Infection with MR766 caused moderate induction in the expression levels of the JNK
protein (Figure 21C), which also acts as a downstream effector molecule and modulator
for the UPR pathway [17].

Figure 21. ZIKV induces DNA damage and ER stress in human astrocytes.
Human astrocytes were infected with ZIKV (MR766, R103451, and PRVABC59) at an
MOI of 0.1. After 48 hpi, RNA was extracted from cell lysates, and RT-PCR arrays were
performed to determine RNA expression of genes involved in human unfolded protein
response pathway. (A) Genes significantly altered by ZIKV infection are presented in the
graph. (B and C) Immunoblotting for protein expression of DDIT3 and JNK from cell
lysates from uninfected and ZIKV infected human astrocytes. Data are presented as mean
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± SEM from 3 independent experiments and analyzed using one-way ANOVA with
Bonferroni post hoc correction. *p <0.05 Vs Control.
We further analyzed the activation and phosphorylation of the proteins involved in
the ER-stress and UPR pathways by western blot (Figure 22A-F). The Uganda strain
(MR766) caused upregulation of the protein kinase R (PKR)-like endoplasmic reticulum
kinase (PERK), inositol-requiring enzyme 1α (IRE-1α) and activating transcription factor6 α (ATF6α) proteins, while infection with the Honduran strain induced expression of IRE1α and ATF6α. The Puerto-Rican strain induced PERK and IRE-1α. Increased
phosphorylated PERK (p-PERK) was detected with the Asian strain of ZIKV; however,
phospho-IRE-1α was not increased with any of the viral strains. The cleaved form of
ATF6α was slightly increased with Uganda (MR766) and Honduras (R103451) strains
(Figure 22A-F). Overall, the data showed that ZIKV induces the UPR pathway by
probably by activation and phosphorylation of PERK.

79

Figure 22. ZIKV induces unfolded protein response in human astrocytes through
PERK.
Immunoblotting for the detection of protein expression and phosphorylation of PERK,
expression, and phosphorylation of IRE-1α, and activation and cleavage of ATF-6α in
human astrocytes after 48 hpi with ZIKV at MOI of 0.1. Data are presented as mean ± SEM
from 3 independent experiments and analyzed using one-way ANOVA with Bonferroni
post hoc correction. *p <0.05 Vs Control.
4.3.2. Inhibition of UPR pathway suppresses ZIKV replication in human astrocytes
In order to investigate the role of UPR pathway in ZIKV infection and associated
immune inflammatory response, we downregulated UPR using siRNA against PERK, the
protein activated by ZIKV in our current study and has previously been reported to
influence ZIKV mediated pathology in neurons [7]. The siRNA mediated downregulation
of PERK resulted in a significant decrease in ZIKV replication in human astrocytes (Figure
23A). However, the decrease was less than one log10. Silencing of PERK caused a slight
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increase in IP-10 secretion in ZIKV (PRVABC59) infected human astrocytes (Figure
23B). Since the effect of PERK silencing was minimal on ZIKV infection, and the secretion
of IP-10 did not correlate with viral titers, we explored for other cellular pathway involved
in ZIKV infection.

Figure 23. Silencing of PERK slightly reduces ZIKV replication in human
astrocytes.
TLR3 in the human astrocytes was knocked down by siRNA against TLR3 using
lipofectamine 2000 transfection reagent. The cells (both knocked down and parental
astrocytes) were infected with ZIKV at MOI of 0.1. (A) RT-PCR using ZIKV specific
primers was performed to determine viral titers from the RNA extracted from the
supernatants. (B) Secretion of IP-10 was measured by ELISA from the supernatants
collected at 48 hpi. Data are presented as mean ± SEM from 3 independent experiments
and analyzed using one way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs
Control.
4.3.3. ZIKV induce TLR3 signaling pathway in human astrocytes
Toll-like receptors (TLRs) are essential signaling pathways involved in the innate
immune defense mechanism since they recognize and respond to pathogens. Despite the
fact, little is known about TLR-mediated ZIKV replication and pathology in glial cells.
Modulation of the TLR pathway by ZIKV-infection in primary human astrocytes was
examined by gene expression profiling (Figure 24A), and protein expression was
confirmed by western blot (Figure 22B-F). mRNA expression profile showed upregulation
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in the levels of TLR3 with Asian strains, upregulation in TLR4 with all three strains and
down-regulation of TLR5 with all three strains of ZIKV. Also, the ETS transcription factor1 (ELK1), which is activated by MAPK signaling and involved in multiple functions
ranging from neuronal differentiation to chromatin remodeling [18], was increased with
MR766, however, was decreased by PRVABC59 (Figure 24A). Similarly, mRNA
expressions of genes involved in TLR signaling pathways such as TICAM2, IRF3, ECSIT,
EIF2K2, and HSPA1A were induced by the Uganda strain, whereas IRF3, ECSIT, FOS,
and IFN-β were upregulated by the Puerto-Rican strain. On the other hand, Pellino-1, a
regulator of TLR signaling pathway [19], was downregulated with the Uganda strain
(MR766) (Figure 24A).

Figure 24. ZIKV perturbs TLR signaling pathway in human astrocytes.
(A) Human astrocytes were infected with different (indicated) strains of ZIKV at MOI of
0.1, and cellular RNA was extracted after 48 hpi for determining the expression of genes
involved in TLR signaling pathway by RT-PCR. A 2-fold change in gene expression was
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used as a cut off value. Immunoblotting for the detection of protein expression of TLRs
(TLR-3, 4 and 5) and the TLR adaptor proteins TICAM1 and MyD88 in human astrocytes
after 48 hpi with ZIKV at MOI of 0.1. Data are presented as mean ± SEM from 3
independent experiments and analyzed using one way ANOVA with Bonferroni post hoc
correction. *p <0.05 Vs Control.
Together with mRNA expression, TLR3 protein expression levels were also
upregulated by around 3-fold in astrocytes infected with either R103451 or PRVABC59
(Figure 24B), TLR4 protein expression was upregulated by approximately 2-folds with all
three strains (Figure 24C), while minor changes were detected in TLR5 expression level
(Figure 24D). An adaptor protein involved in the TLR signaling pathways, TICAM1 and
MyD88, were significantly increased in astrocytes infected with the Puerto Rican strains
(PRVABC59) (Figure 24E and F). TICAM1, which is the adaptor protein involved in the
TLR3 signaling pathway, was also induced by the other Asian strain (R103451).
4.3.4. ZIKV induces activation of IRF3 and nuclear localization of NF‐κB
Since the activation of TLR3 and recruitment of adaptor proteins leads to downstream
signaling pathway involving the activation of two important transcription factor, IRF3, and
NF‐κB, we next measured the effect of ZIKV on the expression of these factors. We
detected increased expression of IRF3 in ZIKV infected astrocytes indicating that activated
TLR3 pathway induces IFN responses via IRF3 induction (Figure 25A). NF‐κB is a
regulator of the immediate early host-pathogen inflammatory and cell survival responses
[20, 21]. We detected a significant upregulation in protein expression of NF-κB in human
astrocytes infected with the Puerto-Rican strain (PRVABC59) (Figure 25B). Activation of
NF-κB is followed by degradation of associated inhibitory molecule IκBα and nucleation
localization of NF-κB for transcriptional regulation of various genes. Therefore, we
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examined both the cytoplasmic and nuclear fraction of the NF-κB by western blot and
immunofluorescence labeling of NF-κB (p65) of the infected astrocytes. We observed
increased nuclear localization of NF-κB in the astrocytes infected with each of the ZIKV
strains (Figure 25C-E).

Figure 25. ZIKV induces downstream signaling molecules in the TLR3 signaling
pathway; IRF3 and NF-κB.
(A and B) Immunoblotting for the detection of protein expression of TLR3 downstream
signaling molecules (IRF3 and NF-κB) in human astrocytes after 48 hpi with ZIKV at MOI
of 0.1. (C and D) Cytoplasmic and nuclear fractions of NF-κB. (E) Immunofluorescent
staining of human primary astrocytes with antibody for GFAP, and NF-κB, to determine
nuclear and cytoplasmic localization of NF-κB. DAPI was used for labeling nuclei. Data
are presented as mean ± SEM from 3 independent experiments and analyzed using oneway ANOVA with Bonferroni post hoc correction. *p <0.05 Vs Control.
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4.3.5. TLR3 regulates ZIKV replication in human astrocytes
Since TLR3 is the highest up-regulated protein in our experiments and is reported to
be involved in viral infection and associated pathogenesis [22], we investigated whether
this receptor protein is involved in ZIKV replication and associated inflammatory
responses in astrocytes. We induced TLR3 signaling by using TLR3 agonist poly I: C
before and during infection with ZIKV. TLR3 signaling was downregulated by genetic
silencing with siRNA against the TLR3 (Figure 26A) or with pharmacological inhibitor (a
thiophenecarboxamidopropionate compound), which inhibits TLR3/dsRNA complex
formation. Following the respective treatment, astrocytes were infected with three different
strains of ZIKV as mentioned earlier. Though statistically insignificant, induction of TLR3
with agonist slightly increased the replication of ZIKV. Whereas, genetic and
pharmacological inhibition of TLR3 signaling showed a significant decrease in viral titers
in the supernatant collected from the cells infected with each of the three strains with the
African (MR766) strain showing the greatest decrease in viral titer after silencing with
siRNA (Figure 26B).
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Figure 26. Silencing of TLR3 reduces ZIKV infection and replication.
Human astrocytes were infected with three different strains of ZIKV (MR766, R103451,
and PRVABC59) at an MOI of 0.1. Sets of the experiment included astrocytes treated with
5μg/mL of Poly I: C (TLR3 agonist), or with TLR3 silenced with siRNA (A) or inhibited
with a thiophenecarboxamidopropionate compound (TLR3/dsRNA complex inhibitor). (B)
RNA was extracted from the supernatant and RT-PCR using ZIKV specific primers was
performed to determine viral titers. (C) ZIKV infectivity was measured by
immunofluorescent staining of ZIKV Env protein and an astrocyte marker GFAP after 24
hpi with PRVABC59 strain. Data are presented as mean ± SEM from 3 independent
experiments and analyzed using one-way ANOVA with Bonferroni post hoc correction. *p
<0.05 Vs Control.
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Similarly, we measured the ZIKV (PRVABC59) infectivity in the presence of
TLR3 agonist or antagonist. We observed a similar trend with a slight increase in infectivity
with TLR3 agonist and a decrease in infectivity with TLR3 antagonist. However, the
changes in infectivity were not significant (Figure 26C). The data indicate that TLR3 is
involved in ZIKV replication but not necessarily in viral entry or permissiveness in the
astrocytes.
4.3.6. TLR3 regulates ZIKV associated host immune inflammatory responses in
human astrocytes
Next, we asked whether TLR3 also mediates ZIKV-induced inflammatory molecules
secretion in human astrocytes. Similar to the previous experiment, we induced TLR3
signaling by using poly I: C and downregulated TLR3 by siRNA against the TLR3 or with
the pharmacological inhibitor in human astrocytes. We measured the selected
inflammatory molecules in the supernatant collected from the control and the infected
astrocytes after 48hpi. We observed that inhibition of TLR3 caused a significant decrease
in ZIKV-induced IFN-β, RANTES, IP-10 and IL-6 secretion by the Puerto Rican strain
(PRVABC59) in astrocytes (Figure 27). On the other hand, exposure with the TLR3
agonist, Poly I: C significantly increased the secretion of IFN-β, RANTES, and IP-10 in
the supernatant of ZIKV-infected astrocytes (Figure 27).
To confirm whether the role of TLR3 signaling in ZIKV infection is limited to
astrocytes or the same applies to other glial cells, we further examined its role in human
microglia by using genetic silencing approach. We knocked down TLR3 with siRNA in
microglia followed by infection with three different strains of ZIKV. A decrease in viral
titers and secretion of inflammatory molecules was observed in human microglia after
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downregulation of TLR3 (Figure 28A-D), suggesting that TLR3 regulates ZIKV
replication as well as ZIKV-induced secretion of inflammatory molecules in the glial cells.
We confirmed downregulation of the entire TLR3 signaling pathway with TLR3
knockdown in astrocytes exposed to ZIKV infection. TLR3 knockdown in astrocytes
reverted ZIKV-induced upregulation of the adaptor protein TICAM1, transcription factor
IRF3 and the alternative adaptor protein MyD88 (Figure 29). The data suggest that
activation of the TLR3 signaling pathway is involved in ZIKV replication and associated
neuropathologies.

Figure 27. Silencing of TLR3 reduces ZIKV-induced antiviral and inflammatory
molecules secretion.
Human astrocytes were infected with three different strains of ZIKV (MR766, R103451,
and PRVABC59) at an MOI of 0.1. Sets of the experiment included astrocytes treated with
5μg/mL of Poly I: C (TLR3 agonist), or with TLR3 silenced with siRNA or inhibited with
a thiophenecarboxamidopropionate compound (TLR3/dsRNA complex inhibitor).
Secretion of inflammatory molecules (IFN-β, IP-10, RANTES, and Il-6) was measured by
ELISA from the supernatants collected at indicated time points. Data are presented as mean
± SEM from 3 independent experiments and analyzed using two-way ANOVA with
Bonferroni post hoc correction. *p <0.05 Vs Control, # p <0.05 Vs ZIKV alone.
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Figure 28. TLR3 regulates ZIKV replication and inflammatory response in human
microglia.
(A) ZIKV titers measured by RT-PCR after 48hpi and TLR3 silencing. (B-D)
Inflammatory molecules measured by ELISA after 48 hpi with or without siRNA against
TLR3. Mock (PBS) infected cells were used as a control and the infection dose of ZIKV
was at an MOI of 0.1. Data are presented as mean ± SEM from 3 independent experiments
and analyzed using one way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs
ZIKV.
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Figure 29. Silencing of TLR3 reverts ZIKV-induced upregulation of downstream
signaling molecules.
TLR3 in the human astrocytes was knocked down by siRNA against TLR3 using
lipofectamine 2000 transfection reagent. The cells (both knocked down and parental
astrocytes) were infected with ZIKV at MOI of 0.1 and the protein expression of TICAM1,
IRF3 and MyD88 were measured by immunoblotting after 48 hpi. Data are presented as
mean ± SEM from 3 independent experiments and analyzed using one way ANOVA with
Bonferroni post hoc correction. *p <0.05 Vs Control, # p <0.05 Vs ZIKV alone.
4.4. Discussion
Once viral genomes are released into the target cells subsequently after entry, the
flavivirus replication complex is assembled in close vicinity to the ER membranes.
Following viral replication and processing of the polyprotein, packaging occurs on the
surface of the ER and resulting immature virions are translocated to the Golgi complex
where furin-mediated cleavage of prM to M generates mature virus which is released from
the cells by exocytosis [23]. However, the host defense mechanisms within the cell create
an adverse environment for the virus, and the virus has to evade or manipulate the cellular
response for their survival and replication [24]. Of those defense mechanisms, the TLR
pathway and the ER stress-related pathways are two important innate defense mechanisms
operated within the cells to create an antiviral state and minimize the effects of viral toxicity
[4, 25].
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In the current study, we reported that ZIKV induces ER stress and activates UPR.
In line with our study, extensive rearrangement of ER membrane and collapse of ER
cisternae juxtaposed with viral particles and virus-induced vesicles has been recorded by
others using electron tomography, indicating that ZIKV replicates in the vicinity of the ER
membranes [26]. We show that ZIKV mediated UPR activation mainly involves activation
and phosphorylation of PERK, though minor activations in IRE-1α and ATF-6α was noted
depending on the viral strains. We also reported that siRNA mediated silencing of PERK
showed a slight but significant decrease in ZIKV replication. Our findings correlate with a
previous study showing a reversal of ZIKV mediated neurogenic effects in mouse
embryonic brain with PERK inhibitor [7]. However, the minimal effects of PERK on ZIKV
replication with no significant effects on the secretion of inflammatory molecules, suggest
a limited role of the UPR pathway in ZIKV infection. ZIKV mediated inductions in ER
stress and related pathways might be the consequences of viral infection and replication
inside the cells and may not necessarily control viral replication and associated pathology.
Exploring for alternative pathway involved in ZIKV infection, we detected that
TLR3 was induced by the Asian strains of ZIKV in astrocytes. Similar to our findings,
previous studies have shown the upregulation of TLR3 by ZIKV in various cell types
including human astrocytes, skin fibroblast and mouse neurospheres [12, 27, 28]. TLR3
which recognizes viral dsRNA has an important role in flaviviral replication and associated
pathology [22]. We also reported that silencing or pharmacological inhibition of TLR3
caused a significant decrease in RNA copies of both Asian and African strains of ZIKV
with correlated decreases in the viral-induced inflammatory response, supporting the role
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of TLR3 in ZIKV replication and associated inflammatory immune response, irrespective
of the strains.
Recently, a study reported that ZIKV-mediated over-activation of TLR3 leads to
the depletion of neural progenitor cells in human cerebral organoids [12, 29], further
validating our findings. Besides ZIKV infection, the role of TLR3 has already been
reported for the closely related viruses such as WNV and DENV. TLR3 knock out mice
are reported to be less vulnerable to severe WNV infection, cytokine production, neuronal
injury and viral replication in the brain [22]. However, a protective role of TLR3 in WNV
and DENV infection has also been reported by other groups [30, 31]. Studies have shown
that TLR3 modulates virus permissiveness, replication, disease severity, immunogenicity
in various other viruses including DENV, WNV, Influenza A virus, HIV-1, Herpes
simplex, suggesting that TLR3 function is not specific to ZIKV [31-35].
TLR3 signaling leads to the activation of IRF3 which induces type 1 IFN responses,
which is a primary antiviral defense strategy of the body. However, studies have shown
that ZIKV nonstructural proteins disrupt the JAK-STAT signaling pathway to evade the
type I IFN effector functions. Therefore, despite the induction of type 1 IFN production by
activated TLR3, ZIKV replication might not be controlled. However, TLR3 mediated NFκB activation and the resulting exaggerated, and persistent secretion of inflammatory
molecules may facilitate neuroinflammation leading to neuropathologies associated with
ZIKV. Differential levels of activation of NF-κB might also explain the differential levels
of secretion of inflammatory molecules by the three spatiotemporally different ZIKV
strains reported in chapter 2. NF-κB is also reported to repress the expression of DDIT3,
possibly limiting the DNA repair mechanism following ER stress [36, 37]. Silencing of
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TLR3 downregulates the entire downstream signaling pathway that is induced by TLR3,
which is supported by a decrease in TICAM1 and IRF3 protein expression. Though TLR3
signaling is generally independent of MyD88, which was downregulated upon silencing of
TLR3, a possible explanation might be siTLR3 suppressed the viral titers to the levels
which may not be sufficient to induce MyD88.
In summary, ZIKV strains differentially activated the TLR pathway regulating the
host innate immune defense. Attenuating TLR3 caused a decrease in viral replication that
correlated with the decreased amount of in viral replication, making TLR3 a potential target
for ZIKV therapeutic approach.
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CHAPTER 5: ROLE OF AUTOPHAGY PATHWAY IN ZIKV INFECTION AND
ASSOCIATED NEUROPATHOLOGY
5.1. Introduction
Autophagy is a complex process of lysosomal degradation of unfolded or
misfolded proteins, intracellular pathogens, and dysfunctional organelles via the
formation of a double membrane structure known as an autophagosome. Autophagy
pathway which involves more than 30 autophagy-related (ATG) proteins [1], is crucial
for multiple cellular activities such as cellular development and differentiation [2],
innate and adaptive immunity [3, 4], and programmed cell death (type II) [5, 6]. The
autophagosome fuses with endocytic and lysosomal compartments to form autoendosome or autolysosome for subsequent degradation [7].
As a part of the host innate stress response, autophagy is frequently a by-product
of viral infection-triggered cellular stress. During viral infection, autophagy is activated
by the innate immune system to degrade and dispose of invading viruses. A selective
form of autophagy referred to as xenophagy is directly involved in the recognition and
lysosomal degradation of the intracellular microorganisms via autophagosomes [8].
Autophagy pathway also facilitates viral antigen presentation leading to the induction
of adaptive immune responses. However, the membrane-bound protected platform of
the autophagosome along with the autophagy generated metabolites is hijacked by many
viruses for their shelter and replication [8, 9]. Viruses have evolved various strategies
to combat or exploit the autophagy pathway for their replication [8].
Several viruses including Poliovirus, hepatitis C virus, Dengue virus, and
coronaviruses are known to subvert the autophagy pathway into a pro-viral mechanism.
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However, the exact mechanism by which autophagy contributes to viral infection is still
unclear [9]. In case of ZIKV infection, induction of autophagy is reported by others in
different cell types including HeLa cells, fibroblast, fNSCs and placental trophoblastic
cells potentially mediated by NS4A and NS4B proteins through inhibition of the AktmTOR signaling pathway [10, 11]. Inhibiting the autophagy pathway with 3methyladenine (3-MA), chloroquine or gene silencing targeting the autophagy-related gene
(ATG-3 and ATG-5) resulted in a decrease in viral replication in various cell types. While,
induction of autophagy with rapamycin promoted ZIKV replication [10, 11]. These
findings present preliminary evidence that ZIKV infection induces autophagy pathway
potentially leading to increased ZIKV replication and viral load.
In the current study, we reported that ZIKV induces the autophagy pathway in
human primary astrocytes. However, autophagy pathway is not directly involved in
ZIKV replication in astrocytes. Nevertheless, genetic and pharmacological inhibition of
autophagy or the autophagy protein, Beclin1, resulted in exacerbation of ZIKV
associated inflammatory responses in the astrocytes. These data indicate that unlike
other viruses, ZIKV has not evolved mechanism to subvert the autophagy pathway in
order to facilitate its replication.
5.2. Methodology
5.2.1. Reagents
Rapamycin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and used at a
concentration of 2.5µM. 3-methyladenine (3-MA) and chloroquine (CQ) were used at a
concentration of 1µM and 40μM, respectively. The concentrations were based on the doseresponse viability assay performed in our previous studies [12, 13].
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5.2.2. Immunoblotting
Primary antibodies against Beclin1 (Cat. ab62557 (1:1500), Abcam, Cambridge,
MA, USA), LC3B (Cat. 12741 (1:1000), Cell Signaling, Danvers, MA, USA),
p62/SQSTM1 (Cat. ab91526 (1:2000), Abcam, Cambridge, MA, USA), ZIKV anti-E (Cat.
GTX133314, (1:1000) Genetex, Irvine, CA, USA), were followed by incubation with a
respective secondary antibody conjugated to horseradish peroxidase (Millipore, Billerica,
MA, USA) used at specified dilution.
5.2.3. Cell-based LC3B assay for autophagosome and autolysosome
LC3B localization analysis for human astrocytes was performed by using
Premo™ Autophagy GFP-RFP-LC3B cell-based assay (Life Technologies, Cat. No.
P36241). The cells were plated at the desired density, allowed to adhere to and infected
with ZIKV. After infection, LC3B sensor was added at a concentration of 30 particles per
cells (PPC) and incubated overnight. DAPI was used to label cell nuclei. Fluorescently
labeled cells were visualized using an inverted fluorescent microscope (Zeiss). Yellow
puncta representing autophagosome and red puncta representing autolysosome were
counted and expressed as number per cells.
5.2.4. Silencing of Beclin1 in human astrocytes
Human primary astrocytes were transfected with siRNA against Beclin1 using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) or Fugene HD (Promega, Madison,
WI, USA) for Beclin1 knockdown. siRNA and transfection reagent (ratio, 1:2) were preincubated for 20 min in OptiMEM medium before addition to the seeded cells. Knockdown
of targets was confirmed in cell lysates by western blot for the protein expression of
Beclin1. CRISPR-cas9 method of silencing was also utilized for enhanced silencing of
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Beclin1 in human astrocytes. Guide RNA (gRNA) for BECN1 and Cas9 enzyme were
mixed in the ratio of 1.3:1 and incubated at room temperature for 5 minutes to make RNPcomplex, followed by incubation with transfusion reagent (Fugene HD, Promega,
Madison, WI, USA) for 20 minutes. The resulting RNP-transfection solution was added to
the seeded cells and incubated for at least 24 hours before ZIKV infection.
5.2.5. Statistical analysis
Results are reported as mean ± SEM of 3–6 independent experiments each
with more than three samples. Data were analyzed using analysis of variance (ANOVA)
followed by appropriate post hoc test for multiple comparisons (Graph Pad Software, Inc.,
La Jolla, CA, USA). An alpha level (p-value) of < 0.05 was considered significant.
5.3. Results
5.3.1. Autophagy is induced in ZIKV-infected human astrocytes
Viral infection is known to activate the autophagy pathway, which can be an attractive
target for various viruses [14, 15]. Induction of autophagosome formation in various cell
types infected with different strains of ZIKV has already been reported [16, 17]. However,
the effect of ZIKV on glial cell-autophagy is not reported yet. To this end, we measured
the protein expression of key proteins involved in the autophagy pathway in human
astrocytes with or without ZIKV infection (Figure 30). Infection of astrocytes with
MR766, R103451, and PRVABBC59 strains of ZIKV showed about 1.3, 1.6 and 1.9-fold
increase respectively, in the expression of Beclin1, a major protein involved in the initiation
of autophagosome formation. LC3B-II, a marker for autophagosome formation [12, 18]
was also increased by about 2-fold, while p62/SQSTM1, a ubiquitin-binding scaffold
protein that facilitates binding of ubiquitinated protein to autophagosome and a marker for
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autophagosome degradation, was upregulated by about 1.5 fold (Figure 30) in astrocytes
infected with all three strains of ZIKV.

Figure 30. ZIKV induces autophagosome formation and blocks autophagosomelysosome fusion.
Human astrocytes were infected with three different strains of ZIKV (MOI = 0.1), cell
lysates collected at 48 hpi and protein expression of Beclin1, LC3B and p62/SQSTM1 were
measured by western blot. Data are presented as mean ± SEM from 3 independent
experiments and analyzed using one-way ANOVA with Bonferroni post hoc correction. *p
<0.05 Vs Control.
Analysis of the autophagy pathway using a cell-based assay that utilizes the tandem
mRFP-GFP tagged LC3 reporter plasmid for fluorescence analysis (Figure 31A-C)
showed similar results with upregulation in autophagosome formation in astrocytes
infected with each of the ZIKV strain. The tandem mRFP-GFP LC3 assay employs the
differential pH stability of green fluorescent protein (GFP) and a red fluorescent protein
(RFP) in an acidic environment of the lysosome. We measured a 2-fold increase in
autophagosome formation in astrocytes infected with R103451 and PRVABC59 strains of
ZIKV, as indicated by the yellow puncta (Figure 31A and B) and a decrease in the
maturation or lysosomal pathway in cells infected with each of the strains (Figure 31A and
C), as detected by a decrease in red puncta. Overall, we showed activation of the autophagy
pathway in cells infected with each strain of ZIKV. The western blot and cell-based assay
data imply that infection by ZIKV induces the initial activation and maturation stages of
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the autophagy pathway, yet, blocks the autophagosome-lysosome fusion and degradation
of the cargo. This, in turn, prompted us to further examine the role of autophagy pathway
in ZIKV infectivity and pathology in human astrocytes.

Figure 31. ZIKV mediated autophagosome induction and subsequent blockade in
autophagosome-lysosome fusion confirmed by the cell-based assay.
(A) Representative images of uninfected and ZIKV (three strains) infected human
astrocytes shows yellow and red LC3B puncta as determined by a cell-based assay for
LC3B. (B and C) The numbers of yellow and red puncta from the cell-based assay were
counted per cells. Presence of both green and red (yellow) fluorescence indicates
autophagosome, while red fluorescence only indicates autolysosome. Data are presented
as mean ± SEM from 3 independent experiments and analyzed using one-way ANOVA
with Bonferroni post hoc correction. *p <0.05 Vs Control.
5.3.2. Modulation of the autophagy pathway has minimal effect on ZIKV infection
in human astrocytes
Next, we explored the role of autophagy in mediating ZIKV replication and associated
pathogenesis in glial cells by using pharmacological and genetic approaches to modulate
the autophagy pathway in ZIKV-infected human astrocytes. Cell supernatants were
collected at 48 hpi, and RNA titer (indicative of viral replication) of each viral strain was
determined by RT-PCR and confirmed by the plaque-forming assay. Induction of the
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autophagy pathway with rapamycin, an autophagy activator, caused a slight but
insignificant increase in the viral titer of R103451. No further changes were detected in the
viral titer of MR766 and PRVABBC59 in the astrocytes treated with rapamycin. Blocking
the formation of autophagosome with 3-MA did not affect ZIKV replication irrespective
of the viral strains. Exposure with chloroquine (CQ), a lysosomotropic agent that inhibits
lysosomal degradation, caused a slight but insignificant decrease in the replication of
PRVABC59 in human astrocytes (Figure 32).

Figure 32. Modulation of Autophagy pathway shows no significant changes in viral
replication.
The autophagy pathway was modulated before ZIKV infection either by using
pharmacological inducer (rapamycin) or inhibitors (3-MA or chloroquine), and viral titers
were measured by RT-PCR using cell supernatants collected after infection with three
different strains of ZIKV and indicated treatments. Data are presented as mean ± SEM
from 3 independent experiments and analyzed using one-way ANOVA with Bonferroni
post hoc correction.
We detected a significant decrease in MR766-induced secretion of IFN-β with
similar trends in other strains with rapamycin indicating a probable role of the mTOR
signaling pathway in IFN response. Exposure to 3-MA did not affect ZIKV-induced IFNβ secretion in the astrocytes. However, exposure with chloroquine caused a significant
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increase in R103451- and PRVABC59-induced secretion of IFN-β (Figure 33A).
Similarly, exposure to CQ enhanced the ZIKV-induced secretion of IP-10 in astrocytes
infected with each of the viral strains (Figure 33B). Except for the decrease in
PRVABC59-induced RANTES secretion, 3-MA had no significant effect on ZIKV
mediated inflammatory molecules (Figure 33C). There are minor changes in ZIKVinduced secretion of IL-6 with rapamycin, 3-MA and CQ (Figure 33D).

Figure 33. Modulation of Autophagy pathway shows a minor effect in ZIKV
mediated secretion of inflammatory molecules.
Human astrocytes exposed either to rapamycin or 3-MA or chloroquine were infected with
three different strains of ZIKV. Cell supernatants collected after 48 hpi were used to
measure IFN-β, IP-10, RANTES, and IL-6 by ELISA. Data are presented as mean ± SEM
from 3 independent experiments and analyzed using one-way ANOVA with Bonferroni
post hoc correction. *p <0.05 Vs Control, # p <0.05 Vs ZIKV alone.
5.3.3. Silencing of Beclin1 exacerbates ZIKV induced inflammatory responses in
human astrocytes without affecting ZIKV replication
Next, we examined the role of Beclin1 in the pathology of ZIKV since we have
previously reported that Beclin1 regulates the replication and viral-induced neuro-
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inflammation in glial cells infected with the Human Immunodeficiency virus [19-21]. We
silenced the expression of Beclin1 by CRISPR/cas9 and siRNA against Beclin1, and the
knockdown was confirmed by western blot (Figure 34A). Although, all three strains of
ZIKV induced the expression of Beclin1 (Figure 30), silencing with CRISPR-Cas9 did not
affect the ZIKV replication in astrocytes (Figure 34B).

Figure 34. Silencing of Beclin1 does not affect the replication of ZIKV.
(A) Beclin1 in the human primary astrocytes was knocked down using small interfering
RNA (siRNA) against Beclin1 or clustered regularly interspaced short palindromic repeats
(CRISPER)/cas9 with guide RNA specific for Beclin1. (B) The astrocytes with or without
Beclin1 knockdown was infected with three different strains of ZIKV, and viral RNA was
measured in the supernatant collected at 48 hpi. Data are presented as mean ± SEM from
3 independent experiments and analyzed using one-way ANOVA with Bonferroni post hoc
correction. *p <0.05 Vs Control.
Similarly, Secretion of IFN-β was not affected by Beclin1 silencing (both siRNA and
CRISPR mediated) in human astrocytes (Figure 35A). However, silencing Beclin1 further
enhanced ZIKV-induced secretion of inflammatory molecules, IP-10, RANTES, and IL-6
(Figure 35B-D). The effect of Beclin1 knockdown in the secretion of IP-10 was not very
high (Figure 35B), but there was up to 7-fold increase in RANTES (Figure 35C), and up
to 12-fold increase in IL-6 (Figure 35D) secretions in the astrocytes with Beclin1
knockdown. Moreover, silencing of Beclin1 caused increase secretion of RANTES and IL-
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6 even in uninfected astrocytes, indicating the anti-inflammatory or protective role of
Beclin1.
Overall, the increase in the release of inflammatory molecules did not correlate with
the viral titer in the astrocytes suggesting that ZIKV-induced inflammatory responses are
not mediated by the autophagy pathway, but by Beclin1 via a different mechanism. The
data further show that the basal level of Beclin1 protein is necessary to control the
exaggerated secretion of cytokines and chemokines. However, our data do not rule out the
possibility that silencing of Beclin1 itself may induce inflammatory molecules secretion in
primary astrocytes.

Figure 35. Silencing of Beclin1 exacerbates ZIKV-induced inflammatory responses
in human astrocytes.
Beclin1 in the human primary astrocytes was knocked down using siRNA against Beclin1
or CRISPER /cas9 with guide RNA specific for Beclin1. The astrocytes with or without
Beclin1 knockdown was infected with three different strains of ZIKV, and the indicated
inflammatory molecules were measured in the supernatant collected at 48 hpi. Data are
presented as mean ± SEM from 3 independent experiments and analyzed using one-way
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ANOVA with Bonferroni post hoc correction. *p <0.05 Vs Control, # p <0.05 Vs ZIKV
alone.
5.3.4. Induction of autophagy pathway by ZIKV is potentially mediated via the
TLR3 pathway
Since the TLR signaling pathway is reported to induce the autophagy pathway [22] via
adaptor proteins MyD88 or TICAM, we next investigated a potential link between TLR3
and the autophagy pathway in the context of ZIKV infection and pathology. Attenuation
of TLR3 by genetic silencing resulted in a decrease in the expression levels of Beclin1
(Figure 36A) suggesting a potential interaction between the proteins involved in TLR
signaling and autophagy pathway or inhibition of a common protein necessary for the
induction of both the pathways. Interestingly, silencing TLR3 caused a further increase in
the protein expression levels of p62/SQSTM1 (Figure 36B) suggesting the accumulation
of autophagosomes. The accumulation of autophagosomes might result from the
suppression of autophagy pathway added to the ZIKV-induced blockade in the completion
of basal autophagy [23]. Overall, our data suggest that TLR3 mediates autophagy in ZIKVinfected astrocytes, although TLR3 mediated ZIKV replication may be independent of the
autophagy pathway.
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Figure 36. Silencing of TLR3 reverts ZIKV-mediated autophagy induction.
Protein expression of Beclin1 and p62 was measured by western blot at 48 hpi in TLR3
silenced astrocytes infected with three different strains of ZIKV. Data are presented as
mean ± SEM from 3 independent experiments and analyzed using one-way ANOVA with
Bonferroni post hoc correction. *p <0.05 Vs Control, # p <0.05 Vs ZIKV alone.
5.4. Discussion
Autophagy, as an innate defense mechanism, has the potential to restrict viral
replication. However, viruses including flaviviruses evolve specific mechanisms to
overcome autophagic degradation [24]. Our data showed that ZIKV induces the autophagy
pathway with possible blockage of autophagic clearance in human astrocytes, irrespective
of viral strains. Our findings are in concordance with what others have reported in different
cells [25, 26]. Since, astrocytes are the predominant cell types in the brain and are involved
in diverse functions including maintenance of the homeostasis, enhancement of the
myelination, the synapses and the blood-brain barrier, any impairment of the autophagy
pathway in astrocytes may contribute to neuronal dysfunction.
However, modulation of the autophagy pathway did not affect ZIKV replication
in human astrocytes, unlike the data reported by others using fNSCs, HeLa cells and MEF
cells [10, 11]. The possible explanation for the anomalies might be variations in the viral
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strains, passage numbers, and sources of the astrocytes, MOI of virus used and other factors
or the effects are cell-type specific. However, we observed minor viral strain-specific
changes in the secretion of inflammatory molecules by rapamycin, 3-MA or chloroquine
exposed human astrocytes. MR766-induced IFN-β secretion was decreased by rapamycin,
while R103451-induced IFN-β secretion was increased by chloroquine. Similarly,
exposure to chloroquine enhanced the secretion of IP-10 induced by R103451 and
PRVABC59 strains of ZIKV. These data indicate that the autophagy pathway is associated
with ZIKV induced inflammatory responses without directly altering the viral replication.
Silencing of Beclin1 caused further enhancement in the secretion of RANTES, IP-10, and
IL-6, which may be related to any cellular mechanism involving Beclin1 other than the
autophagy pathway.
Both the autophagy and the TLR3 pathways are important mediators of the innate
immune response, and we report that ZIKV induces both the pathways. Activation of TLR3
was previously reported to induce the autophagy pathway [22, 27-29]. MyD88 and
TICAM1, two adaptor proteins involved in the TLR signaling pathway can interact with
the autophagy protein, Beclin1 with this interaction inhibiting the binding between Beclin1
and the anti-apoptotic protein, B-cell lymphoma 2 (BCL-2). Dissociation of Beclin1 from
BCL-2 by activated MyD88 or TICAM1 may facilitate the induction of the autophagy
pathway, while autophagic processing of viral RNA, in turn, may activate TLR3 signaling
pathway [29]. A decrease in ZIKV-induced expression of Beclin1 by TLR3 silencing in
the current study support that TLR3 pathway mediates autophagy pathway directly or
indirectly via an unknown mechanism. Increase in p62/SQSTM1 with TLR3 silencing in
ZIKV infected astrocytes might also suggest the role of p62/SQSTM1 to facilitate
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clearance of viral proteins via the ubiquitin-proteasomal system, while the autophagy
pathway is downregulated [23].
Overall, we report that ZIKV strains differentially activated the autophagy,
important mechanisms involved in regulating the host innate immune defense. Modulation
of the autophagy pathway caused changes in ZIKV-induced inflammatory responses,
which did not correlate with the viral titer released from human astrocytes. Autophagy
pathway to some extent and Beclin1 play a protective role in ZIKV mediated inflammation.
Together with the findings in chapter III, the data indicate that ZIKV-mediated induction
of autophagy pathway is probably associated with the TLR3 signaling pathway.
References
[1]

Ojha CR, Lapierre J, Rodriguez M, Dever SM, Zadeh MA, DeMarino C, et al.
Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological
Disorders: New Insights for Diagnosis and Therapeutic Applications. Viruses.
2017;9(7).

[2]

Tsukamoto S, Kuma A, Murakami M, Kishi C, Yamamoto A, Mizushima N.
Autophagy is essential for preimplantation development of mouse embryos.
Science. 2008;321(5885):117-20.

[3]

Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Tolllike receptor 4 is a sensor for autophagy associated with innate immunity.
Immunity. 2007;27(1):135-44.

[4]

Shibutani ST, Saitoh T, Nowag H, Munz C, Yoshimori T. Autophagy and
autophagy-related proteins in the immune system. Nat Immunol.
2015;16(10):1014-24.

[5]

Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, et al. Regulation of an ATG7beclin 1 program of autophagic cell death by caspase-8. Science.
2004;304(5676):1500-2.

[6]

Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death.
Cell death and differentiation. 2005;12 Suppl 2:1528-34.

110

[7]

Kaur J, Debnath J. Autophagy at the crossroads of catabolism and anabolism.
Nature reviews Molecular cell biology. 2015;16(8):461-72.

[8]

Choi Y, Bowman JW, Jung JU. Autophagy during viral infection — a doubleedged sword. Nature Reviews Microbiology. 2018;16(6):341-54.

[9]

Heaton NS, Randall G. Dengue Virus and Autophagy. Viruses. 2011;3(8):1332.

[10]

Liang Q, Luo Z, Zeng J, Chen W, Foo S-S, Lee S-A, et al. Zika Virus NS4A and
NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem
Cells to Inhibit Neurogenesis and Induce Autophagy. Cell Stem Cell. 19(5):66371.

[11]

Cao B, Parnell LA, Diamond MS, Mysorekar IU. Inhibition of autophagy limits
vertical transmission of Zika virus in pregnant mice. The Journal of Experimental
Medicine. 2017;214(8):2303-13.

[12]

El-Hage N, Rodriguez M, Dever SM, Masvekar RR, Gewirtz DA, Shacka JJ.
HIV-1 and Morphine Regulation of Autophagy in Microglia: Limited Interactions
in the Context of HIV-1 Infection and Opioid Abuse. 2015.

[13]

Rodriguez M, Lapierre J, Ojha C, Estrada-Bueno H, Dever S, Gewirtz D, et al.
Importance of Autophagy in Mediating Human Immunodeficiency Virus (HIV)
and Morphine-Induced Metabolic Dysfunction and Inflammation in Human
Astrocytes. Viruses. 2017;9(8):201.

[14]

Jheng JR, Ho JY, Horng JT. ER stress, autophagy, and RNA viruses. Front
Microbiol. 2014;5:388.

[15]

Blázquez A-B, Escribano-Romero E, Merino-Ramos T, Saiz J-C, Martín-Acebes
MA. Stress responses in flavivirus-infected cells: activation of unfolded protein
response and autophagy. Frontiers in Microbiology. 2014;5:266.

[16]

Liang Q, Luo Z, Zeng J, Chen W, Foo S-S, Lee S-A, et al. Zika Virus NS4A and
NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem
Cells to Inhibit Neurogenesis and Induce Autophagy. Cell stem cell. 2016;0:144554.

[17]

Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, et al.
Biology of Zika Virus Infection in Human Skin Cells. Journal of virology.
2015;89:8880-96.

[18]

Mizushima N, nmizu.phy2@tmd.ac.jp, Department of Physiology and Cell
Biology TMaDU, Tokyo 113-8519, Japan, Yoshimori T, Department of Cellular

111

Regulation RIfMD, Osaka University, Osaka 565-0871, Japan, Levine B, et al.
Methods in Mammalian Autophagy Research. Cell. 2010;140(3):313-26.
[19]

Dever SM, Rodriguez M, Lapierre J, Costin BN, El-Hage N. Differing roles of
autophagy in HIV-associated neurocognitive impairment and encephalitis with
implications for morphine co-exposure. Frontiers in Microbiology. 2015;6:1-15.

[20]

El-Hage N, Rodriguez M, Dever SM, Masvekar RR, Gewirtz DA, Shacka JJ.
HIV-1 and morphine regulation of autophagy in microglia: limited interactions in
the context of HIV-1 infection and opioid abuse. Journal of virology.
2015;89:1024-35.

[21]

Rodriguez M, Lapierre J, Ojha CR, Estrada-Bueno H, Dever SM, Gewirtz DA, et
al. Importance of Autophagy in Mediating Human Immunodeficiency Virus
(HIV) and Morphine-Induced Metabolic Dysfunction and Inflammation in Human
Astrocytes. Viruses. 2017;9(8).

[22]

Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors
control autophagy. EMBO J. 2008;27(7):1110-21.

[23]

Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, et al. p62 links the autophagy
pathway and the ubiqutin–proteasome system upon ubiquitinated protein
degradation. Cell Mol Biol Lett. 2016;21.

[24]

Chiramel AI, Brady NR, Bartenschlager R. Divergent Roles of Autophagy in
Virus Infection. Cells. 2013;2(1):83-104.

[25]

Zhang Z-W, Li Z-L, Yuan S. The Role of Secretory Autophagy in Zika Virus
Transfer through the Placental Barrier. Frontiers in Cellular and Infection
Microbiology. 2016;6:206.

[26]

Chiramel AI, Best SM. Role of autophagy in Zika virus infection and
pathogenesis. Virus Research. 2017.

[27]

Daffis S, Samuel MA, Suthar MS, Jr. MG, Diamond MS. Toll-Like Receptor 3
Has a Protective Role against West Nile Virus Infection. Journal of Virology.
2008.

[28]

Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, et al. Toll-like
receptors 9 and 3 as essential components of innate immune defense against
mouse cytomegalovirus infection. Proceedings of the National Academy of
Sciences. 2004.

[29]

Shi C-S, Kehrl JH. MyD88 and Trif Target Beclin 1 to Trigger Autophagy in
Macrophages. Journal of Biological Chemistry. 2008;283:33175-82.

112

CHAPTER 6. INFECTION WITH ZIKV CAUSES GROWTH AND BRAIN
ABNORMALITES IN THE PUPS OF AUTOPHAGY-DEFICIENT MICE
6.1. Introduction
ZIKV is a neurotrophic flavivirus associated with microcephaly and other fetal
neurological disorders collectively known as Congenital Zika Syndrome [1-3]. Although
most human infections of ZIKV are typically transmitted by the Aedes mosquito, some
virus can also spread through sexual contact, blood transfusion [4-7] and through vertical
transmission from infected pregnant mothers to their fetuses [8-10]. Similar to the infection
caused by other arboviruses such as DENV or CHIKV, ZIKV-infected individuals
typically develop mild symptoms. Unlike other arboviruses, in-utero exposure with ZIKV
can cause congenital malformations in the fetus such as microcephaly [11, 12], and other
overt congenital abnormalities including fetal death, placental insufficiency, fetal growth
restriction and central nervous system injury [13].
Microcephaly is a neurodevelopmental disorder in newborns, characterized by an
abnormal smaller sized head when compared to babies of the same sex and age. The
significant reduction in brain size accompanied by intellectual disability are believed to be
caused by impaired cell proliferation and the death of cortical progenitor cells and their
neuronal progeny [14]. Genetically, microcephaly is linked to the alterations in genetic loci
microcephalin (MCPH). Twelve of the MCPH loci (MCPH1-MCPH12) including
microcephalin-1 (MCPH1), the WD repeat-containing protein 62 (WDR62), the CD5
regulatory subunit associated protein 2 (CDK5RAP2), the cancer susceptibility candidate
5 (CASC5), the abnormal spindle-like primary microcephaly (ASPM) have been already
mapped [15]. Many of these genes encode proteins localized at the centrosome or with
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centrosome-related activities and play an important role in cell cycle progression, cell
division and formation of the mitotic spindle [16]. More importantly, significant
downregulation of several of the microcephaly-associated genes was detected in ZIKVrelated studies [17-19], suggesting a direct mechanistic link of ZIKV infection to
microcephaly at the molecular level.
Despite the outpouring literature related to in utero transmission of ZIKV, little
work has been done to elucidate mechanism associated with ZIKV-induced neurological
deficits during gestation. Furthermore, how viral particles and other causal factors
transmigrate across the placental barrier and the blood-brain barrier, inflicting
neuropathology in the fetus, is still unclear. Recently we have shown that ZIKV can
modulate the autophagy pathway in glial (astrocytes and microglia) cells while silencing
of the autophagy gene, beclin1 leads to increased inflammation in ZIKV-infected glia [2022]. Beclin1 is a component of the phosphatidylinositol 3-kinase nucleation complex which
regulates the initiation stages of the autophagy pathway [23]. Autophagy is a multi-step
intracellular degradative system which delivers cytoplasmic contents including misfolded
proteins, dysfunctional organelles and components of pathogens to lysosomes. The process
is characterized by the formation of the autophagosome, a unique double-membrane
structure, which is degraded upon fusion with lysosome [23]. A malfunction in this
pathway has been implicated in a number of neurological diseases such as Alzheimer’s and
Parkinson’s diseases as well as in human immunodeficiency virus (HIV)-associated
neurological disorders [24].
The goal of the studies proposed in Aim 3 was to explore the role of autophagy
pathway, specifically the protein Beclin1 in the mechanism associated with ZIKV-induced
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abnormal fetal development during gestation using ZIKV-infected timed-pregnant wildtype C57BL/6J and Beclin1 deficient (Atg6+/-) mice. We report for the first time that three
different phylogenetic strains (Honduras-R103451, Puerto Rico-PRVABC59 and UgandaMR766) of ZIKV infect timed-pregnant Beclin1 (Atg6+/-) deficient and wild-type
(C57BL/6J) animals, while only pups born to ZIKV-R103451-infected dams exhibit
growth impairment, specifically those born to viral-infected Atg6+/- dams. Our data indicate
that significant downregulations of the microcephaly related genes MCPH1, ASPM,
WDR62, and CASC5 in the brains and significant increases in pro-inflammatory cytokines
secreted by the glial cells are associated with impaired growth and brain development of
the pups born to ZIKV-infected autophagy deficient mice. We detected ZIKV NS1 and
Env protein in pup’s brain in the absence of ZIKV genome.
6.2. Materials and Methods
6.2.1. Ethics statement
Animal work was conducted in accordance with the guidelines of the National
Institutes of Health (NIH) guide for the care and use of laboratory animals. Animal
experiments and associated protocols were reviewed and approved by the Florida
International University institutional animal care and use committee (IACUC).
6.2.2. Animal model and timed pregnancy
C57BL/6J (stock # 000664) and B6.129X1-Becn1tm1Blev/J (stock # 018429) mice
on a C57BL/6J background were procured from The Jackson Laboratory (Bar Harbor, ME,
USA) and bred in the animal facility at Florida International University. For the timedpregnancy studies, male and female mice aged 8 to 15 weeks were kept isolated for at least
24 hours before mating. After 24 hours, females were introduced into the breeding cage
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with the male in the early evening and monitored periodically for 48 hours after initial
introduction to detecting for the presence of a vaginal plug as an indication of mating. The
day on which the plug is observed is considered day zero (E0) and mouse weight was
recorded every three days to ensure the pregnancy. Pregnant dams received anti-IFNAR1
mouse monoclonal antibody (MAR-5A3, Leinco Technologies) at 2mg/Kg body weight
via intraperitoneal (IP) route at gestational date of E8 followed by subcutaneous (SC)
injection with 103 Plaque Forming Unit (PFU) of ZIKV (R103451) in 50µL of PBS or PBS
only (mock) at gestational date of E9. A booster dose of anti-IFNAR1 at 0.5mg/Kg dose
was administered by IP at 2 and 4 days’ post-infection. In one set of experiment, pregnant
dams (N=8) were sacrificed, and maternal placenta and organs including the liver, spleen,
heart, and brain from both mother and fetus were collected post-mortem on gestation day
E17. In the other set of experiment, pregnant dams (N=8) were allowed to deliver their
pups, which were monitored through 6 weeks of age for any signs of ZIKV infection
including evaluation of postnatal growth. Tissues (brain, kidney, and liver) harvested postmortem were snap frozen for molecular and histopathological analysis (Figure 37).
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Figure 37. Experimental design for mouse infection model.
Timed pregnancy was set up and monitored for the duration of gestation. On embryonic
day 9 (E9) animals were treated with IFNAR antibody (2mg/kg, IP). On E10 animals were
challenged with ZIKV by subcutaneous route (103 PFU/50µL) on foot pad. Mock animals
received 50µL PBS. On E11 and E13, booster doses of IFNAR antibody were administered
to animals (0.5mg/kg, IP). Blood was collected on E13 for ZIKV titer detection. On E17,
dams were sacrificed for collection of the fetus and vital organs including placenta, while
another set of experiments, pregnant dams were allowed to deliver their pups which were
monitored for potential growth impairments. Pregnant dams (N=10/strain) delivered (N=58) pups.
6.2.3. Real-Time PCR
Viral RNA from serum and tissues collected at various time-points from both
ZIKV-infected and uninfected animals were extracted using QIAamp Viral RNA mini kit
(Qiagen, Valencia, CA, USA). Cellular RNA was extracted by RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). Viral RNA was amplified using iTaq universal SYBR Green onestep PCR kit (Bio-Rad, USA) and 10μM of the ZIKV primers (Sigma-Aldrich, USA). A
standard curve was prepared from a 10-fold dilution of previously quantified ZIKV stock
solution with known titer, and viral titer was expressed as RNA copies equivalent of log10

117

PFU/mL. MCPH1, ASPM, CASC5, and WDR62 gene expressions were measured from
total RNA extracted from fetal and pup brain using RT-PCR.
Primer sequences
ZIKV: Forward: 5’-CCGCTGCCCAACACAAG-3’
Reverse: 5’-CCACTAACGTTCTTTTGCAGACAT-3’
MCPH1: Forward 5′- AAGAAGAAAAGCCAACGAGAACA-3′
Reverse 5′-CTCGGGTGCGAATGAAAAGC-3',
ASPM: Forward 5′-CCGTACAGCTTGCTCCTTGT-3′
Reverse 5’-GGCGTTGTCCAATATCTTTCCA-3’,
CASC5: Forward 5’-TCGCTGAAGTGGAAACAGAAAC-3’
Reverse 5’-TATCTGAGCAAGGGTCTCTGCG-3’
WDR62: Forward 5’-GCTGACAAATGGCAAGCTG-3’
Reverse 5’-GATGGTCTTGAGGGGTTCCT-3’.
6.2.4. Labeling with Hematoxylin & Eosin
Brain tissues from ZIKV-infected and non-infected pregnant dams and their
offsprings were each embedded using optimal cutting temperature (OCT) compound.
Cryostat sectioned slices of 5-micron thickness were stained with hematoxylin and eosin
(H&E) as described previously by us [25]. Briefly, tissues were exposed to xylene and rehydrated with absolute ethanol, 95 and 70% ethanol, followed by staining with
hematoxylin dye for 15 min, before washing with distilled water. Tissues were stained with
eosin for 20 secs, dehydrated with gradient ethanol after washing with tap water, and
tissues were then cleared by xylene and mounted using mounting media for visualization.
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Images were acquired using a Zeiss (Germany) inverted fluorescence microscope with a
560 Axiovision camera using 20, 40, or 63X objectives.
6.2.5. Murine mixed glial cell culture
For primary murine glial culture, post-natal day 4-6 (P4-P6) ATG6+/- mice and
C57BL/6 littermates were separated according to phenotypic coat color and sacrificed
according to IACUC guidelines as described previously by us [26]. Growth medium
contained Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA,
USA) supplemented with glucose (2 mg/mL; Sigma-Aldrich), Na2HCO3 (6 mM;
Invitrogen), 10% v/v heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT,
USA), and 1% penicillin/streptomycin (100 U/mL / 100 µg/mL; Invitrogen) [27]. Striata
were isolated and dissociated mechanically and enzymatically with 0.25% trypsin
containing DNase (2.5 mg/ml) centrifuged, triturated, and twice filtered through 40-micron
nylon mesh cell strainer. Cells were then plated and maintained in plates coated with PolyL-lysine (0.1mg/ml). Cultures were maintained for 5-10 days at 37˚C and 5% CO2.
6.2.6. Statistical analysis
Results are reported as mean ± SEM of three independent experiments. Data were
analyzed using analysis of variance (ANOVA) techniques followed by appropriate post
hoc test for multiple comparisons (GraphPad Software, Inc., La Jolla, CA, USA). An alpha
level (p-value) of < 0.05 was considered significant.
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6.3. Results
6.3.1. Timed-pregnant transiently immunosuppressed C57BL/6J and Atg6+/- mice
were susceptible to ZIKV infection
We explored the role of the autophagy pathway in ZIKV infection using timedpregnant Beclin1-deficint (ATG6+/-) and wild type (C57BL/6J) mice model. A schematic
diagram of the experimental design with various end-point is shown in Figure 37 and is
described in the material and methods section. IFNAR1 blocked pregnant dams were
infected with ZIKV (R103451) at a dose of 103 PFU in 50µL of PBS. We selected the viral
strain R103451 based on the higher infectivity of the strain to mice compared to other
strains (MR766 and PRVABC59) and its close relation with the Brazilian strain. The body
weights of each pregnant mouse were measured before the detection of a vaginal plug and
throughout the gestation period in order to confirm the pregnancy and weight gain patterns
in pregnant dams (Figure 38A). Interestingly, infection of beclin1 deficient (Atg6+/-) dams
with all three strains of ZIKV showed relatively less gain in body weight compared to wild
type (C57BL/6J) dams, although both strains delivered an equal amount of offspring (N =
5 - 8) per litter. It is important to point out that the size of a litter delivered by the Atg6+/dams (crossed with an Atg6+/- sire) is controlled genetically. Approximately, 50% of the
pups delivered will be heterozygous for the beclin1 gene (Atg6+/-) with a brown coat, 25%
will be homozygous for the Beclin1 gene Atg6+/+ with a black coat, while 25% will not
express the beclin1 gene (Atg6-/-) and die in utero. Next, we monitored the survival rates
of infected dams for up to three weeks. ZIKV-infected Atg6+/- dams showed significantly
lower survival rate compared to mock-infected Atg6+/- as well as ZIKV-infected C57BL/6J
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dams (Figure 38B). Likewise, the increased fatality was observed in animals infected with
the other viral strains, specifically after infection with ZIKV-MR766 (Figure 39A).
Viral infection measured in serum collected on E13 or 4 dpi by RT-PCR showed
viremia levels in the range of 103 PFU/mL in both wild type and Atg6+/- dams with no
significant difference between strains (Figure 38C). Analysis of viral titers in various
organs removed post-mortem on E17 showed levels of viral RNA in the following order:
placenta > spleen > liver > heart with the lowest titer detected in the brain, irrespective of
mice strains, indicating that ZIKV infection or replication in infected mice is not dependent
on Beclin1 (Figure 38D). We did not detect measurable ZIKV titer in the brain nor any
other vital organs collected post-mortem from pups born to ZIKV-infected C57BL/6J and
Atg6+/- dams.

Figure 38. ZIKV establish productive infection in numerous organs of wild type and
Beclin1 deficient pregnant mice.
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(A) Body weight gain of wild type C57BL/6 and Atg6+/- pregnant dams after detection of
vaginal plug. (B) Survival curve of C57BL/6 and Atg6+/- pregnant dams after infection
with ZIKV (R103451) compared with respective mock infected pregnant dams. (C) ZIKV
titers in the serum from infected dams as measured by RT-PCR on E13 and expressed as
RNA copies equivalent to log10 PFU/mL. Numbers are based on a standard curve prepared
from known viral stocks. (D) ZIKV titers measured by RT-PCR using RNA extracted from
different organs removed post-mortem from infected dams sacrificed on E17. Data are
presented as mean ± SEM from 3 independent experiments and analyzed using one-way
ANOVA with Bonferroni post hoc correction. *p <0.05 Vs control.

Infection with phylogenetically different strains of ZIKV (PRVABC59 and MR766) also
showed similar viral titers in serum and organs removed postmortem (Figure 39B and C).
However, infection with ZIKV- PRVABC59 showed significantly lower viral titer in
serum of Atg6+/- dams compared to their wild-type counterparts (Figure 39B). Since we
detected high mortality among the dams infected with ZIKV-MR766, we sought to confirm
that the observed mortality was caused by ZIKV infection using IFNAR1 knock-out mice
infected with increasing doses (101, 102, 103 and 104 PFU/ml) of ZIKV-MR766. We
detected an infection-dose dependent decrease in survival rate of the mice (Figure 39D).
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Figure 39. Infection with Different strains of ZIKV (MR766 and PRVABC59).
Percent survival of C57BL/6 and Atg6+/- pregnant dams (A) after infection with ZIKV
(MR766 and PRVABC59) compared with mock infected dams. (B) Viral RNA isolated
from serum was used to analyze viral titer by RT-PCR. (C) Cellular RNA extracted from
organs removed post-mortem was used to analyze viral titer by RT-PCR. C57BL/6 (black
bars) and Atg6+/- (brown bars). (D) Percent survival from IFNAR-/- knockout mice infected
with MR766 (101 to 104 PFU/mL) shows 100% mortality on Day-12 post infection. N = 8
pregnant dams per group. Error bars show mean  SEM for 3 independent experiments.
*p<0.05 vs. respective mock infected pregnant dams and #p<0.05 vs. C57BL/6J (Two-way
ANOVA followed by Tukey’s test).
6.3.2. Beclin1 deficiency impairs survival and growth in offspring exposed to ZIKV
in utero
The major concern related to ZIKV is its association with neurodevelopmental
disorders and growth retardation in newborns and infants. Impaired autophagic pathway in
the brain is often associated with neurodegenerative disorders including viral
neuropathogenesis [24]. However, whether the autophagy pathway enhances or protects
ZIKV-mediated impairment in fetal growth is still not explored. To this end, pups born
from mock and ZIKV-infected C57BL/6J and Atg6+/- dams were monitored for mortality
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and adverse morphological abnormalities by measuring body weight and length, for up to
21 days after birth. A slight decrease in the survival rate of pups born to ZIKV-infected
C57BL/6J and Atg6+/- dams was noted (Figure 40A). Pups born to ZIKV-PRVABC59 and
ZIKV-MR766-infected dams did not show significant differences in survival rate (Data not
shown).
Next, we monitored the survived pups born from ZIKV and mock-infected dams
until three weeks of birth. Growth development, as measured by the body weight and
length, was similar among survived pups born to mock and ZIKV-infected C57BL/6J dams
(Figure 40B). Morphological abnormalities as indicated by lower body weight and length
was detected after 14 days post birth in the pups born to Atg6+/- dams infected with ZIKVH (Figure 40C and D). The visible difference in body size was detected in 1 of every 3.54
(25-30%) pups (within the same litter) born to ZIKV-H-infected Atg6+/- dams. Pups born
with growth and brain impairment were brown coated and heterozygous for the beclin1
gene (Atg6+/-) (Figure 40C). The average body weight in these pups was around 6.8 gm as
compared to 8.0 gm which is a typical weight of a 3 week old mouse. The average body
length of the lean pups was also significantly smaller measuring at around 5.30 cm as
compared to 6.01 cm which is a typical weight of a 3 week old mouse (Figure 40D). It is
important to note that no significant growth abnormalities were measured in pups born to
mock infected dams or dams infected with the ZIKV-PRVABC59 and the ZIKV-MR766,
irrespective of murine strains (data not shown). After 21 days, both small and typical sized
pups were sacrificed and brains were removed for further analysis. As expected, brain
removed from the smaller sized pups were significantly smaller in size and grossly
underdeveloped almost liquid in consistency, while the brains from the typical sized pups
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had a well-defined brain and solid in consistency (Figure 40C). Overall, the data show that
attenuation of autophagy, and the protein Beclin1 leads to growth and brain impairment in
pups exposed in utero to the ZIKV (R103451).

Figure 40. Beclin1 deficiency impairs survival and growth in offspring exposed to
ZIKV in utero.
A) Survival curve of pups born to ZIKV-infected and mock-infected wild types and /or
Atg6+/- dams. (B) Body weight and length of pups born from wild type dams measured at
day 7, 14 and 21. (C) Representative images of pups born to Atg6+/-dams exposed to PBS
(1) or ZIKV (2) in utero showing significant delay in growth and brain development. (D)
Body weight and length of pups born from Atg6+/- dams measured at day 7, 14 and 21.
Data are presented as mean ± SEM from 5 independent experiments and analyzed using
two-way ANOVA with Bonferroni post hoc correction. *p <0.05 Vs respective mock
control.
6.3.3. Expression of microcephalic genes was decreased in offspring exposed to ZIKV
in utero
Exploring potential causal factors associated with the growth and brain impairment
detected in pups born to ZIKV-H-infected Atg6+/- dams, we first measured viral titers in
various organs from pups removed post-mortem. Although viral RNA was not detected
(data not shown), the non-structural (NS) protein-1 and structural protein (Env) were
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detected in postmortem brain of the pups exposed to ZIKV in utero (Figure 41A).
Microscopic appearance of the frontal cortex stained with H&E showed no visible sign of
aberrant morphology of neurons in mock-infected brain tissues removed post-mortem
(Figure 41B_ top panel). In contrast, ZIKV-infected brain tissues showed signs of necrotic
neurons with shrunken neuronal cell bodies (Figure 41B_bottom panel).

Figure 41. Expression of microcephalic genes was decreased in offspring exposed to
ZIKV in utero.
(A) Representative images of brain tissues labeled by immunofluorescence. Red color
represents the microtubule-associated protein 2 (MAP-2) indicator of mature neurons, the
green color represents ZIKV Structural protein (Env) and Non-structural protein-1 (NS-1),
and the blue color indicates DAPI-labeled nuclei. (B) Hematoxylin & Eosin (H&E)
staining of brains removed post-mortem exposed to PBS (top panel) and ZIKV (bottom
panel) in utero. Representative images were acquired at 20 and 40X magnification. (C)
RNA expression of the microcephaly associated genes (MCPH1, ASPM, WDR62, and
CASC5) were measured by RT-PCR. C57BL/6 (black bar) and Atg6+/- (brown bar). Error
bars show mean  SEM for 3 independent experiments. The data were analyzed by Twoway ANOVA followed by Tukey’s multiple comparison test. *p<0.05 vs. respective mock
infected strain, #p<0.05 vs. C57BL/6J.
Expression levels of microcephaly (MCPH) related genes previously linked to
stillbirth, brain development, and microcephaly in ZIKV-exposed fetus [33, 34] were
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measured in post-mortem brain tissues of pups exposed to ZIKV infection in utero. A
decrease in RNA expression levels of about 2.5-fold in MCPH1 and ASPM and about 1.7fold in CASC5 were detected in post-mortem brain tissues of pups exposed to in utero
ZIKV infection when compared to post-mortem brain tissues exposed to PBS (Figure
1Figure 41C). Interestingly, expressions of the MCPH related genes in brain tissues
removed post-mortem from pups born to ZIKV-infected Atg6+/- dams were further reduced
by about 3-fold compared to pups born from ZIKV-infected C57BL/6J dams (Figure 41C).
Overall, the data showed significant impairment in the expression of the
microcephalic related genes, which may be associated with the increased mortality rate and
growth retardation in offspring born from ZIKV-infected Atg6+/- dams.
6.3.4. Beclin1 deficiency enhances the secretion of inflammatory molecules in ZIKVinfected mouse mixed glial cells
Since glial cells are the principal cell types involved in the release of
neuroinflammatory molecules, they are usually considered the culprit in many viral
pathology and autophagy pathway might influence the levels of inflammatory molecules
secretion by infected glial cells [35, 36]. To this end, mixed glia (astrocytes and microglia)
were isolated from the whole brain of either C57BL/6J or Atg6+/- pups and seeded as
previously described by us [26]. First, we measured infectivity of ZIKV (R103451) in the
glial cells and showed that murine mixed glial cells were permissive to ZIKV infection
(Figure 42A), irrespective to murine strain. Secretion of the inflammatory chemokines
RANTES and MCP-1 and the cytokine IL-6 were measured in non-infected, and ZIKV
(R103451)-infected (MOI of 0.1) glial culture supernatants by ELISA and showed a
significant increase in inflammatory molecules at 24, 48 and 72 hpi with ZIKV infection
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(Figure 42B). Significant differences in ZIKV-induced secretion of inflammatory
molecules were detected between glia derived from Atg6+/- pups when compared to glia
derived from C57BL/6J pups. After twenty-four hours, secretion of RANTES was 2.5-fold,
MCP-1 was 1.4-fold, and IL-6 was 1.6-fold higher in ZIKV-infected glia derived from
Atg6+/- pups when compared to similar treated glia derived from C57BL/6J pups (Figure
42B). More importantly, the secretions of RANTES and MCP-1 in supernatant derived
from Atg6+/- glia infected with ZIKV (R103451) remained significantly higher throughout
the experiment (Figure 42B).

Figure 42. ZIKV infects mixed mouse glia and induces inflammatory molecules.
(A) Representative images of mouse glia from C57BL/6 and Atg6+/- pups infected with
ZIKV (MR766, R103451, and PRVABC59) for 24 h and immunofluorescently labeled
with GFAP (green), ZIKV Env (red) and DAPI nucleus (blue). (B-D) Secretion of
RANTES, IL6 and MCP-1 detected in glial supernatants infected with ZIKV (R103451)
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were measured after 24, 48 and 72 hpi by ELISA. Glia derived from C57BL/6 pups (black
bar) and glia derived from Atg6+/- pups (brown bar). Data are presented as mean ± SEM
from 3 independent experiments and analyzed using two-way ANOVA with Bonferroni
post hoc correction. *p <0.05 Vs Control, # p <0.05 Vs C57BL/6J.
6.3.5. Beclin1 deficiency enhances the secretion of inflammatory molecules in NS1,
and Env protein treated mouse mixed glial cells
Since we detected ZIKV proteins (NS1) but not the virion in brains of pup exposed
to ZIKV in utero, we examined whether treatment with a nonstructural protein NS1 and a
structural protein Env induce secretion of inflammatory molecules by the mixed glia. A
protein concentration of 50nM NS1 and Env was selected based on serum concentration of
these proteins reported in a severe flaviviral infection [37]. We found that exposure with
NS1 and Env proteins significantly increased the secretion of RANTES, MCP-1, IL-6 and
TNF-α (Figure 43) in both C57BL/6J-derived and Atg6+/--derived glia. However, similar
to the ZIKV infection, both NS1 and Env proteins had more inflammatory effects on the
Atg6+/--derived glia when compared to C57BL/6J-derived glia. Secretion of TNF-α was
drastically increased in Atg6+/--derived glia after 24 and 96 hpi when compared to similar
treated C57BL/6J-derived glia.
Overall, the data show an important role of the protein Beclin1 in regulating the
release of inflammatory molecules in response to pathogenic insults to the host, and that
attenuating autophagy leads to increased release of inflammatory molecules that could
account for the maladaptive abnormalities detected in pups born from ZIKV infected
Atg6+/- dams.
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Figure 43. ZIKV NS1 and Env proteins cause increased secretion of several
inflammatory molecules in Atg6+/--derived glia.
Secretion of RANTES, MCP-1, IL6 and TNF-α in supernatants of NS1 and Env-treated
mouse glial cells was measured after 8, 24 and 96 hpi by ELISA. Glia derived from
C57BL/6 pups (black bar) and glia derived from Atg6+/- pups (brown bar). Data are
presented as mean ± SEM from 3 independent experiments and analyzed using one-way
ANOVA with Bonferroni post hoc correction. *p <0.05 Vs Control, #p <0.05 Vs
C57BL/6J.
6.4. Discussion
In this study, we reported for the first time that three different phylogenetic strains of ZIKV
infects timed-pregnant Beclin1 (Atg6+/-) deficient and wild-type (C57BL/6J) animals,
while only pups born to ZIKV-R103451- infected Atg6+/- dams showed growth
impairment. Despite the use of anti-IFNAR1 mAb, viral replication was limited in our
immunocompetent mice, which could account for the rare vertical transmission of virion
to embryos and pups. Viral proteins, on the contrary, were observable in post mortem brain
tissues. Autophagy is a common pathway involved in regulating the replication of ZIKV
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as well as other viral-infections in cells of the central nervous system [13, 15, 26-30].
Others have shown restricted ZIKV infection in placenta, with reduced ZIKV-mediated
placental damage and reduced adverse fetal outcomes using an autophagy deficient animal
model lacking the Atg16L gene [31]. The contrasting data suggests that specific proteins
within the autophagy pathway may be involved in ZIKV-pathogenesis.
The mechanism(s) mediating growth and brain impairments with ZIKV infection
are still unclear. Our data showed a significant downregulation of several microcephaly
related genes including MCPH1 and ASPM in post-mortem brains of pups deficient in the
Beclin1 protein, while exposure to ZIKV (irrespective of strains) led to a further decrease
in the expression of MCPH1, ASPM, WDR62, and CASC5. Studies have shown that
mutations in the human WDR62 resulted in microcephaly and a wide spectrum of cortical
abnormalities [32-34], while a loss in the WDR62 protein function in mice causes mitotic
delay, death of neuron progenitor cells, reduced brain size and dwarfism [34]. CASC5 was
shown to be involved in cell cycle and kinetochore formation during metaphase with
mutation in this gene was also implicated in causing microcephaly [35]. Although the exact
mechanism through which Beclin1 or the autophagy pathway causes a reduction in the
microcephaly-related genes is still unknown, Beclin1 and the ultraviolet irradiation
resistance-associated gene (UVRAG) are involved in both autophagy and centrosome
stability. Centrosome instability and impaired autophagy can be linked to ZIKV mediated
microcephaly [36, 37]. A recently identified member of MCPH (MCPH18), a
phosphatidylinositol 3-phosphate-binding protein functions as a scaffold protein for
autophagic removal of aggregated proteins indicating the potential role of autophagy in the
development of primary microcephaly [38]. Using glia derived from beclin1 (Atg6+/-)
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deficient animals we showed higher levels of inflammatory molecules after exposure to
virus and viral proteins. While we cannot conclude that inflammation may lead to abnormal
brain development, others have shown that the presence of viral proteins in the CNS causes
neuroinflammation, glial dysfunction, excitotoxicity, and neuronal death [15, 39].
Ongoing studies are further investigating potential mechanisms mediating growth and
brain impairments with ZIKV infection.
Another enigma is related to the transmigration of ZIKV proteins across the blood
brain barrier. It was recently shown that secretory autophagy or exosome pathways could
be a potential mechanism in virus transfer [40], since spreading of virus and viral toxins
across cells can be facilitated by extracellular vesicles, microvesicles and exosomes [41].
Exosome biogenesis and the autophagy pathway are interlinked pathway and most
importantly, implications of exosome and autophagy interplay in the context of
neurodegeneration has been shown by others [42-44]. While this topic is beyond the scope
of our current project, experimental studies are investigating mechanisms involved in viral
trafficking.
In summary, our study showed a novel autophagy-deficient mouse model of ZIKV
infection and an indirect role of the protein Beclin1 and the autophagy pathway in ZIKV
infection and pathology. Lack of autophagy leads to stillbirth as well as maternal and fetal
death while concurrently enhances ZIKV-mediated growth retardation by regulating the
expression of microcephaly-related genes. Modulating the autophagy pathway can be
employed as a therapeutic approach for ZIKV infection; however, it requires further
understanding of the exact molecular mechanism and exact cellular target of the ZIKVinfection and the associated adverse outcome during pregnancy.
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CHAPTER 7. CONCLUSION AND RECOMMENDATIONS
Despite the myriad of studies focusing on the molecular mechanism of ZIKV infection,
there are many questions that still remain unanswered. The exact mechanisms by which
the virus enters host cells and mediates brain anomalies in fetus and neurological
complications in adults are still not conclusive. We aimed at exploring the molecular
mechanism of ZIKV infection and associated neuropathogensis. In the line with other
evidences our study shows that ZIKV uses Axl receptor for its cellular entry with Tyro3
playing no significant role in ZIKV infection in the glial cells. Besides viral entry, Axl
receptor is involved in ZIKV replication inside the glial cells. The data suggest that
targeting Axl receptor can attenuate ZIKV infection by blocking the cellular entry of the
virus and limiting the replication. However, inhibition of Axl in turn may exacerbate the
ZIKV-induced inflammatory responses. Once ZIKV enters the host, TLR3 senses the virus
and get activated. Activation of TLR3 leads to an antiviral response, however, exaggerated
immune response mediated by hyper-activation of TLR3 may be associated with ZIKV
pathogenesis. Therefore, TLR3 could be a target for therapeutic approach [1].
Upon activation of TLR receptors, a burst of pro-inflammatory cytokines is released,
which then propagates inflammation by stimulating various cytokine receptors, including
type I interferon receptors (IFNAR). Though the inflammatory response is a part of body
immune mechanism, it has to be controlled in terms of time and magnitude to prevent from
the unwanted, detrimental or autoimmune responses. The immune system employs
multiple strategies to turn off or limit the inflammation. One of the crucial mechanism is
the TAM signaling pathways. Activation of TAM receptors by IFNARs via JAK/STAT
pathway dampen inflammatory responses downstream of TLR and cytokine receptors by

139

increasing the expression of the suppressor of cytokine signaling proteins (SOCS).
Therefore, TAM signaling pathways function as mechanisms of negative feedback in
inflammation. Whereas, TAM receptors themselves are under the control of TLR signaling
pathways which assures that the initiation of TAM pathways only occurs at the end stages
of the immune responses, allowing efficient inflammatory responses to occur while
preventing chronic inflammation and concomitant tissue damage [1].
ZIKV activates the autophagy pathway however mediating autophagy pathway by
activation and inhibition of various steps in the pathway might not necessarily inhibit ZIKV
infection. Autophagy protein Beclin1 plays a protective role by suppressing ZIKV-induced
inflammation, controlling the microcephaly associated genes expression in in-utero ZIKV
exposed pups and limiting the congenital ZIKV syndromes and neurodevelopmental
consequences associated with ZIKV. Both the autophagy and the TLR3 pathways are
important mediators of the innate immune response that are activated by ZIKV. The
different receptors in the TLR pathways are the initiators of both innate and adaptive
immune response, while the autophagy pathway clears intracellular pathogens and
facilitates antigen presentation. Since, TLR signaling pathway is reported to induce the
autophagy pathway [2-5], there may be a possible connection between ZIKV induced
TLR3 pathway and autophagy pathway. MyD88 and TRIF, two adaptor proteins involved
in the TLR signaling pathway, can interact with the autophagy protein, Beclin1 and this
interaction inhibit binding between Beclin1 and the anti-apoptotic protein, B-cell
lymphoma 2 (Bcl-2). Dissociation of Beclin1 from Bcl-2 by MyD88 and TRIF induces
autophagy [5], while autophagy processing of viral RNA activates TLR signaling pathway.
Our data further indicate that ZIKV associated autophagy induction is at least partially
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mediated via activation of TLR signaling. ZIKV can also induce ER stress related
pathways depending on the viral strains. In summary, ZIKV can modulate vital cellular
mechanisms including the TLR, UPR, and autophagy pathways, with cumulative
consequences of cellular destruction and clinical manifestations.
We further studied the role of autophagy pathway, specifically the Beclin1, in
development of neuropathology in in-utero ZIKV-exposed fetus by using ZIKV-infected
timed-pregnant wild-type C57BL/6J and Beclin1 deficient (Atg6+/-) mice. We showed that
autophagy pathway or the Beclin1 protein plays a protective role in both growth and
embryonic brain development in the fetus. Beclin1 deficiency contributes to the ZIKVinduced reduction in several microcephalic genes in the brain leading to the overt
congenital malformations and growth impairment in the offspring. Finally, our data
indicate that ZIKV proteins transmigrated from the placenta to the fetus probably via the
secretory autophagy pathway may be the main causal factors for the neurodevelopmental
delay detected in pups born from ZIKV-infected dams.
Despite our effort to explore in detail mechanism of ZIKV infection and associated
neuropathogensis, there are some limitations in our studies. Because of lack of time and
resources, we couldn’t confirm the role of TLR3 and Axl using in-vivo animal model.
Similarly, we are lacking the data for protein expression of microcephaly related genes.
We are still examining the potential role of secretory autophagy or exosome in the
transmigration of ZIKV proteins or genome.
Development of therapeutics requires precise understanding of the biology and
pathogenesis of the virus. The major challenge in ZIKV research is to directly correlate
viral infection with viral induced neurodevelopmental disorders in an immunocompetent
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animal model. Exact cellular and molecular mechanisms of ZIKV pathogenesis may not
be reflective in immunocompromised mice. Therefore, development of a more appropriate
animal model system is essential not only for understanding the biology of infection, but
also for determining the targets for vaccines and therapies. While studying the antiviral
drugs, safety in pregnant woman should also be evaluated because common antivirals and
nucleoside analogs are reported to be unsafe during pregnancy, therefore alternative
therapeutic approaches that target cell signaling pathways can be explored. Based on some
of the current findings, more investigations are necessary to exploit TLR3 and the
autophagy pathways as potential therapeutic targets. Since neurodevelopmental disorders,
neuroinflammation and neurodegenerative consequences are major public health threats
concerning ZIKV infection, drug delivery to central nervous system by employing targeted
drug delivery approaches such as nanoparticles, nanogels, liposomes or implants need to
be studied after the identification of suitable targets.
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